welcome sponsors vc partner 11th annual ......nyse euronext (nyx) is a leading global operator of...

REGIONAL PARTNERSORGANISERS

PARTNERING ORGANISATIONSSPEAKERS

PRESENTING COMPANIES

VC PARTNERW

ELCOME

SPONSORS

11th Annual

BIOTECH IN EUROPE INVESTOR FORUM

www.sachsforum.com

13th-14th September 2011Hilton Zurich Airport Hotel, Switzerland

Conference Guide

BI

OT

EC

H

IN

E

UR

OP

E

IN

VE

ST

OR

F

OR

UM

WELCOM

E

Welcome




VC PARTNERSPONSORS

next u

Request for PresentationsPlease use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Sachs Associates are delighted to welcome you to the:

11th Annual

Biotech in EuropeInvestor Forum13th-14th September 2011Hilton Zurich Airport Hotel, Switzerland

General InformationThe registration desk will be open from 8am on September 13th and from 8.15am on September 14th although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants.

A Networking Lunch will be set up in the Zurich A & B rooms.

Coffee stations will be set up in the Zurich A & B rooms and the presentation rooms throughout the event.

Sachs Associates are delighted to welcome you to the 11th Annual Biotech in Europe Investor Forum. Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas.

This Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe’s Biotech industry.

The programme highlights the current issues surrounding the evolving M&A market, the Private Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, this year’s programme features more than 70 company presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners.

WELCOM

EREGIONAL PARTNERS

ORGANISERSPARTNERING ORGANISATIONS

SPEAKERSPRESENTING COM

PANIESVC PARTNER

SPONSORS

t back

Events Diary

5th Annual European Life Science CEO ForumFor Partnering & Investing28 – 29 February 2012 • Zurich • Switzerland

Back for its fifth year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships.

Building on the success of this year’s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants.

The conference will feature up to 8 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners.

Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives!

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Zoe Harris on [email protected]

SPONSORS

Sponsors




VC PARTNERW

ELCOME

t back :: next uwww.glsv-vc.com

Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

For more information, please see our website: www.glsv-vc.com

Global Life Science Ventures GmbHVon-der-Tann-Str. 3D - 80539 MünchenGermany

Phone +49 (0)89 - 288 151-0Fax +49 (0)89 - 288 151-30

Global Life Science Ventures

SPONSORS

Sponsors




VC PARTNERW

ELCOME

www.nyx.com

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company’s exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products.

With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext’s equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world’s second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500.

For more information, please visit: www.nyx.com

NYSE Euronext

t back :: next u

SPONSORS

Sponsors




VC PARTNERW

ELCOME

t back :: next uwww.ricerca.com

Founded in 1986, Ricerca Biosciences offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from lead identification through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, as well as medicinal chemistry, radiochemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. Our experienced scientists deliver world-class expertise and services to help you shorten time to IND and bring molecules to the clinic faster.

In addition to U.S.-based facilities in Concord, Ohio, and Bothell, Washington, Ricerca also has ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon facility also holds certification from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Discovery PharmacologyMolecular profiling & screeningFunctional pharmacologyEarly cellular toxicologyCellular oncology and immune systemsIn vivo safety and disease modelsDiscovery DMPK

Chemical DevelopmentMedicinal chemistryAnalytical chemistryProcess chemistryEngineering and scale-upRadiosynthesisAPI production with cGMP controls

Drug Safety and MetabolismGeneral toxicologySafety pharmacologyContinuous infusionJuvenile toxicologyDARTBioanalytical services

Ricerca Biosciences7528 Auburn RoadConcord, OH 44077USA

Tel: +1 888 RICERCA (742 3722)Fax: 440 354 6276

Ricerca Biosciences

VC Partner




VC PARTNERW

ELCOME

SPONSORS

Our active ingredient is Innovation

At Merck Serono, we are actively committed to bringing therapeutic innovations to patients. We specialize in the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases and other conditions with unmet medical needs.

Around the world, over 17,000 employees work to discover, develop, manufacture and commercialize Merck Serono’s prescription therapies, available in over 150 countries.

We are internationally recognized as a biotechnology leader, with innovative and successful products along with a well-stocked and promising development pipeline. Specialized know-how in research and production means that we are able to ensure absolutely high-quality manufacturing, a key success factor especially in the biopharmaceutical industry.

In 2007, sales of Merck Serono products generated total revenues of €4.5 billion. We devote 20% of these earnings to the pursuit of innovative new therapies through our own research and development, strategic alliances and agreement.

Merck Serono S.A.9, chemin des Mines Case postale 54 CH-1211 Geneva 20 Switzerland

Tel.: +41-22-414 3000Fax: +41-22-414 2179

Merck Serono International SA www.serono.com

Speakers




VC PARTNERW

ELCOME

SPONSORS

t back :: next u

Tim Haines, Partner, Abingworth LLP

Tim has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth in September 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe. Current and past board positions include Astex Therapeutics, Fovea, IMI, KSpine, PowderMed, Stanmore Implants and XCounter. Tim has a BSc from Exeter University and an MBA from INSEAD. He is a former Director of the Biotechnology Industry Association and currently sits on the Venture Committee of the BVCA. At Abingworth, he identifies and creates new businesses and provides support for portfolio companies.

Jason Avery, Head of Business Development, Affitech AS

Jason is a highly experienced business development executive, specializing in the pharmaceutical/biotechnology sectors. From 2005 to 2007, Jason was the Founder and CEO of Funxional Therapeutics, raising venture capital from leading investors. Jason has also been the founder and CEO of a number of other small start-ups over the last 7 years. Jason was Chief Business Officer at Cambridge Antibody Technology from 1996 to 2003. At CAT, he he was a key member of the Executive Management Team, and was responsible for executing over 25 deals with pharmaceutical and biotechnology companies. Prior to CAT, Jason was with Ernst & Young for 11 years as a Director Corporate Finance & Consultancy, based in London and in Palo Alto near San Francisco.

Jason graduated as a Civil & Structural Engineer, and has qualified as a Chartered Accountant in England. He is a Fellow of The Royal Institution, a member of the Institute of Directors, has a distinction from the Harvard Law School Program on Negotiation. Amongst Jason’s specialties are PR/IR, marketing, strategy, MBOs, M&A, business development, deal structuring, negotiation, competitive intelligence, & alliance management. Jason’s scientific expertise includes platform technology, antibodies, therapeutic proteins, small molecules, inflammatory diseases, oncology, cardiovascular diseases, fixed-dose combinations and bio-similars.

Jason started with Affitech early in 2011.

Katya Smirnyagina, Venture Partner, Alta Partners

Katya Smirnyagina joined Alta in 2002 and focuses on European investment opportunities. She currently represents Alta on the board of directors of Cerenis Therapeutics and Kiadis Pharma. She also led Alta’s investment in Ablynx.

Prior to joining Alta, she worked in business development and finance at Genset, a French genomics-based biotechnology company, where she negotiated a number of licensing agreements and strategic partnerships. Prior to Genset, Katya was a manager with the Mitchell Madison Group, a global management-consulting firm, from 1997 to 2000.

She obtained a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and received her Bachelor of Science in Biochemistry with high honors from Moscow University in Russia. Katya completed her scientific training as a post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of Medicine. She has co-authored a number of scientific papers.

Hans Loibner, CEO, Apeiron Biologics AG

Hans Loibner has acted since 2005 as CEO of Apeiron Biologics AG, a product-oriented biotech company in Vienna, focusing on development of biologic / immunologic treatments of cancer (www.apeiron-biologics.com), with a pipeline of 5 clinical projects up to Phase III and several preclinical projects. In 2004, Loibner founded HL-Bioscience Research GmbH, a consulting company in Vienna specializing in cancer immunotherapy projects. In 1999, Loibner was founder of Igeneon, a cancer immunotherapy company focused on cancer vaccines and monoclonal antibodies, and acted as CEO until mid 2004. Loibner started his career at Sandoz/Novartis in 1977, stayed there until 1999 and held various R&D management positions. Since1985 Loibner is engaged in commercially oriented cancer immunotherapy approaches and developed several projects up to Phase II/III clinical trials. Loibner holds a PhD from the University of Vienna in organic chemistry and is author/coauthorof various scientific papers and (co)-inventor of more than 60 patents.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Markus Hosang, General Partner, BioMedPartners AG

Dr. Markus Hosang is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions in the Pharma R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a VP and CSO of Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee.

He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle. Dr. Hosang served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its Treasurer from 1994-2002. He currently is a member of the boards of Avontec GmbH, Okairos AG and Suppremol GmbH. Earlier he was on the boards of Omrix, Kourion (until its merger with ViaCell), IDEA and Atugen. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents.

Ilka Wicke, Investment Manager, Boehringer Ingelheim

Ilka Wicke joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery approaches. She later joined the Corporate Licensing Division of Boehringer Ingelheim where she over the last 10 years gained extensive experience in the evaluation, negotiation and the management of global licensing transactions. Subsequently Ilka joined the Corporate Licensing group as head of the business advisory teams for oncology, urology and metabolism where she was responsible for the identification and evaluation of pre-clinical and clinical licensing opportunities as well as structuring and negotiating technology and licensing agreements. She later joined the transaction group of Corporate Licensing where she was responsible for the negotiation and conclusion of a variety of global licensing agreements. Ilka has a PhD in organic chemistry from the Johann Wolfgang Goethe University in Frankfurt. Following her graduation she spent a year as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy approaches to stimulate antitumour responses.

Roger Hill, Executive Director – Licensing and Business Development, Boehringer Ingelheim

As Executive Director & Head, Global Licensing – Commercial Opportunities, Dr. Hill’s responsibilities include identifying and executing Business Development & Licensing opportunities that add value to Boehringer Ingelheim’s Prescription Medicine and CHC franchises in both mature and emerging markets. Following extensive Therapeutic Area R&D experiences at Sterling Winthrop Pharmaceuticals and Pfizer Global Research & Development, Dr. Hill transitioned to Business Development at Pfizer, and in 2008 joined Boehringer Ingelheim, based in Ridgefield, CT, USA. As a Business Development & Licensing executive Roger has expertise in product sourcing, due diligence, contract negotiations and legal transactions. Prior to 2007 Dr. Hill was a Research & Development Therapeutic Area Director at Pfizer with leadership responsibility for multiple CardioMetabolic disease areas, including Cardiovascular and Frailty. Dr. Hill was recently nominated to the Irish Government’s 2010 “Life Science Top 50” recognizing influential Irish Americans in life sciences. He holds a Ph.D. degree in Pharmacology from University College Dublin, Ireland, and an MBA in Hi-Tech Finance from Northeastern University, Boston.

Eric Bernhardt, Portfolio Manager, Bellevue Asset Management LLC

Eric Bernhardt joined Bellevue Asset Management in 2009 and has overall management responsibility for the Healthcare segment, which comprises the sub-segments Biotechnology, Medical Technology and Healthcare. Before joining the company, he worked for Julius Bär and from 1997 to 2007 was with Clariden Leu Asset Management, where he managed investment funds specialized in healthcare, biotechnology and generics. Prior to that, he was a pharmaceutical analyst and portfolio manager at UBS. Eric Bernhardt earned a degree in forest engineering from the ETH in Zurich and is a CFA charter holder.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Pnina Fishman, CEO, Can-Fite BioPharma

Prof. Fishman is the scientific founder of Can-Fite and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center. Prof. Fishman is a very accomplished scientist and has authored or co-authored over 140 publications and presented the findings of her research at many major scientific meetings. Her scientific work was the foundation on which Can-Fite was built. This scientific work has gained recognition as one of the leading approaches for new generation therapies for cancer and inflammatory diseases. Her past managerial experience included seven years as CEO of Mor Research Application (MRA), a company that was in charge of commercialization of intellectual property from all hospitals and research centers of Clalit Health Services, the largest healthcare provider in Israel, and was also the first clinical CRO in Israel. She was also involved in the establishment and served on the Board of Directors of several life sciences technology start-ups.

Drew Hofmann, Executive VP & COO, CerMed International

Drew has gained a broad base of executive leadership and business development experience working in entrepreneurial as well as major U.S. and International medical device and diagnostics companies. In addition to his 15 years in senior level Sales and Marketing positions, he has served as CEO/President, COO, and Board member of several medical device and diagnostics companies, one of which he co-founded with business partners in the UK.

He is currently serving as Executive VP, COO of CerMed International, a company focused on changing the future of women’s health specifically in the area of cervical cancer screening the protecting against the HIV virus. Previously, he served for six years as President & CEO of, HeartSine Technologies, a “public access” cardiac defibrillation company, which he co-founded, led from start-up to commercialization, secured several rounds of venture funding and currently serves as a Director. Prior to that he served as President, CEO & Chairman of SenDx Medical, Inc., an early stage Point-of-Care Diagnostics Company, where he competently managed a turn around of the business resulting in consistent growth and the eventual sale of the Company to Radiometer Medical ApS a leading provider of acute care testing solutions headquartered in Denmark.

In addition to his “C” level management experience Drew has an extensive global background leading sales and marketing driven organizations where he assumed and succeeded in positions of increased managerial responsibility by consistently driving significant growth in revenue and earnings.

He served 5 years as Executive VP, & COO of E for M, Medical a NASDAQ listed Medical Device Company focused in the areas of interventional cardiology, electrophysiology, diagnostic cardiac imaging and patient monitoring. During this time he was responsible for a significant increase in revenue and earnings stemming from both organic growth and various strategic alliances and acquisitions, which resulted in a substantial increase in shareholder value and a profitable exit. Just prior to that he served 5 years as VP Sales & Marketing for Burdick Corp., a leading U.S. developer, and manufacturer of diagnostic cardiology devices, where he managed a significant up-turn in the business, more than doubling both revenue and earnings during his tenure and leading to the sale of the business to Siemens medical one of the world’s leading manufacturers of medical equipment headquartered in Germany.

He is an active participant in various business networking and mentoring programs in California.. He has a BS degree in Industrial Management from the University of Baltimore where he also undertook graduate studies in the area of International Marketing and Economics.

Lubor Gaal, Executive Director, Strategic Transactions, Bristol-Myers Squibb

Lubor is Head of Europe, Search and Evaluation and in addition, responsible for Global Transactions, Neurosciences. He is BMS’ point person for pharmaceutical or biotechnology companies in Europe.

Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d, France and CBO of Vectron Therapeutics AG, Germany. In the US, Lubor worked for Berlex Laboratories (NJ) where he was responsible for Global Cardiovascular and CNS Licensing of Schering AG. Before joining Berlex, he worked for Burrill and Company in San Francisco, where he advised biotechnology and pharmaceutical companies on business development strategies and execution. Lubor has extensive experience in evaluating and negotiating transactions with small and large companies, having worked in California, New Jersey and in Europe since the 90’s.

Lubor received his Ph.D. from the University of California at Berkeley and his B.Sc. in Neuroscience from the University of Sussex in Brighton, U.K.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Oliver Schacht, CEO, Curetis

Oliver Schacht, PhD, has spent more than 12 years in the molecular diagnostics industry. He had a distinguished career at Epigenomics AG which he co-founded in 1998. He served as CFO of Epigenomics AG (Berlin, Germany) from 1999 until 2011 and as CEO for Epigenomics, Inc. (Seattle, USA) from 2006 until 2011. He has an extensive track record in strategy development and implementation, fund-raising (including VC rounds, IPO, PIPE, Public Rights Offerings), corporate finance, M&A and alliance negotiation. During his tenture at Epigenomics Oliver was instrumental in negotiating and managing alliances with the likes of Roche, Abbott, QIAGEN, Quest, Sysmex, Merck, Pfizer, J&J and others.

Oliver while managing Epigenomics Inc. as CEO was involved in several clinical studies, including a large, prospective multi-center trial in colorectal cancer screening in the USA and Germany. Oliver built a marketing and sales organization that launched the world’s first blood based colorectal cancer screening IVD test kit.

Oliver holds a diploma in European Business Administration from the European School of Business in Reutlingen and London, as well as a Master’s and Ph.D. degree from the University of Cambridge (UK). During his tenure at Mercer Management Consulting (1995 until 1999), he worked on projects in M&A, growth strategies and reorganization in pharmaceutical, biotechnology, and other sectors. Oliver is also a co-founder of several start-up companies in fields such as biotech, internet, and education.

Ada Kruisbeek, CEO, & CSO, DCPrime BV

Ada Kruisbeek founded DCPrime in 2005 and is responsible for the overall management and strategic decision making of DCPrime. She has more than 30 years of managerial experience in science and business, and is an expert in immunology whose career has been dedicated to immunity against cancer, first in academic settings, and later in industry. Ada Kruisbeek worked at the National Institutes of Health, Bethesda, MD, USA, from 1978 until 1992, at the forefront of research that revealed how the immune system develops. She then became Head of the Department of Immunology at the Nederlands Kanker Instituut-Antoni van Leeuwenhoekhuis (NKI-AVL) in Amsterdam from 1992 till 2001. She published close to 140 papers, many of which appeared in peer-reviewed top-journals, and served on multiple advisory boards of national and international scientific agencies, research institutes and companies. In 2001, she moved to industry and became Senior Vice-President Research at Crucell BV, responsible for building up the cancer antibody pipeline. In 2004, when Crucell closed its oncology programs, Ada Kruisbeek moved to the Vrije Universiteit (VU) in Amsterdam, and founded the Technology Transfer Office (TTO) for the VU & VUmc in 2004, DCPrime in 2005, and the Life Sciences Center Amsterdam in 2007. In less than 5 years, she succeeded in making DCPrime a clinical stage company. DCPrime closed its first financing round in September 2010 and started a Phase I study in AML in April 2011.

Titus Kretzschmar, Chief Scientific Officer, Delenex Therapeutics AG

Dr. Titus Kretzschmar graduated from the University of Hannover/Germany in 1992 (PhD; biochemist). Since then he is working in the biotech/pharma environment. Main affiliations include the Ciba-Geigy AG (Basel), where he set up systems for selection of antibodies by phage display, as well as the MorphoSys AG (Munich-Martinsried), where the work with phage display resulted in the commercialization of the HuCAL GOLD® antibody libraries. In 2004 he was appointed to head R&D of the amaxa AG, a profitable biotech firm that provided leading devices and protocols for the Nucleofection® of cells. After the acquisition of amaxa by the Lonza AG in 2008 he became Lonza’s CSO & Head of LIFT (“Lonza Innovation for Future Technologies”). In the beginning of 2010 he decided to return to the biotech world joining as CSO the Delenex Therapeutics AG based in Zurich-Schlieren, a VC-financed company founded in September 2009 that develops the next generation of antibody fragments for therapeutic applications. In May 2011 Delenex concluded its Series A financing round by securing in total CHF 30.2 millions (USD 34.8; EUR 23.5).

Julian Bertschinger-Ehrler, CEO and Co-Founder, Covagen AG

After his studies in molecular biology and biochemistry at ETH Zurich, Julian Bertschinger joined the group of Prof. Dario Neri at the Institute of Pharmaceutical Sciences ETH Zurich as a Ph.D. student. There he co-invented Covalent DNA Display technology. After obtaining his Ph.D. in May 2005, he continued developing Covalent DNA Display as a postdoctoral fellow in Prof. Dario Neri’s group. In June 2006, Julian Bertschinger was selected from more than 100 applicants as one of the winners of the Venture Leaders Prize founded by the Gebert Rüf Stiftung. This enabled him to join a training program in the Boston area (USA) with a course in entrepreneurship at Babson College. Since 2007, Julian Bertschinger has been serving as CEO of Covagen.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Kees Been, President & CEO, EnVivo Pharmaceuticals

Kees Been has served as president and chief executive officer since 2005 and brings more than 15 years of experience to EnVivo. Prior to joining EnVivo, Kees was chief executive officer of Bionaut Pharmaceuticals, a biotechnology company using a proprietary cell-based discovery platform to advance drug candidates for cancer and inflammation. Prior to his work at Bionaut, Kees spent four years at Biogen where he directed the Oncology Business Unit and, as senior vice president of business development, led all of Biogen’s deal-making efforts and portfolio management activities. Major deals he oversaw include the collaborations with Elan on Antegren® (now Tysabri®), with ICOS on the oral LFA-1 antagonist, and with EOS Biotechnology on breast cancer target discovery. Before his work with Biogen, Kees held executive positions with Monsanto Life Sciences Company, involving corporate modification projects and large growth strategies in Latin America. Prior to that, Kees worked at Gemini Consulting where he last served as vice president and was responsible for building the pharmaceuticals practice. He began his career as a scientist on the Interferon-gamma project at Biogen in Geneva, Switzerland. He earned an M.B.A. degree from INSEAD in France and a B.S. degree in Molecular Biology and Process Engineering from the University of Agriculture in Holland.

Lorenza Castellón, Health & Biotech Equity Analyst, Equity Development Ltd

Lorenza Castellón is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations.

Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international investment organisations.

Jason Rushton, Head of Life Sciences Advisory Initiative, Switzerland, Deloitte LLP

Jason is a Director, Corporate Finance Advisory at Deloitte and leads the Swiss firms life science initiative.

Jason has 18 years of experience in the pharmaceutical sector spanning R&D, management consulting and venture capital.

He began his career in drug discovery with Eli Lilly and then moved to PA Consulting Group where he advised pharmaceutical / biotech clients in technical, commercial due diligence and financial transactions. For the last 10 years Jason has been an active venture capital investor with direct involvement in completing over 30 life science transactions latterly with the venture capital fund of Nestle.

Jason spent several years as a board member of two biotech companies and has firsthand experience of pharma business development and licensing.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Christina Takke, Partner, Forbion Capital Partners

Christina Takke is Partner at Forbion Capital Partners and joined the team at ABN AMRO Capital Life Sciences as analyst in 2000.

Before that Christina worked with Bio-Gen-Tec-NRW in Cologne, Germany, a regional development organization for the biotechnology industry. Here she evaluated business proposals and assisted companies in the fundraising process.

At Forbion Christina is responsible for scouting and analysis of new investment opportunities as well as the general deal execution.

Christina serves on the Supervisory Boards of arGEN-X and Pieris. Previously, she was on the board of Bioceros and was closely involved with GlycArt (sold to Roche in 2005) as Observer.

Christina began her scientific career with a master’s degree in biology from the Technical University of Darmstadt. She subsequently joined the group of Prof Dr, Campos-Ortega at the Institute of Development Biology of the University of Cologne, where she studied the Delta-Notch signaling pathway and its role during zebra fish neurogenesis and early somite development.

Arthur Franken, Partner, GILDE Healthcare Partners

Arthur Franken joined Gilde in 2001. Mr. Franken led the investments in Conatus Pharmaceuticals, FlowCardia (acquired by C. R. Bard, Inc. (NYSE: BCR)) and MTM Laboratories. He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agendia, AMT (IPO on Euronext), BG Medicine, IDEA, Neuro3D (acquired by Evotec) and Pieris.

Mr Franken represents Gilde on the board of MTM Laboratories. He served as a board member for FlowCardia (acquired by C. R. Bard, Inc. (NYSE: BCR)) and observed on the boards of Agendia and AMT (IPO on Euronext).

Prior to joining Gilde Mr. Franken gained experience in cardiovascular research at TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. During his degree, Mr Franken specialized in molecular toxicology at the departments of Toxicology and Biopharmacy in the Leiden/Amsterdam Center for Drug Research. He is a Dutch national.

Beth Jacobs, Managing Partner, Excellentia Global Partners

Beth is the founding Partner of Excellentia Global Partners, a global lifesciences-focused investment bank in New York. In her role overseeing origination and execution of private placements, she has an active dialogue with corporations, financial sponsors, venture capitalists, hedge funds and mutual funds. Beth is also involved in cross border M&A, Licensing and Partnering in the life sciences arena.

Beth has served in senior executive roles in her twenty five years of experience in both investment banking and in the corporate sector. On the advisory side, she was most recently Managing Director / Partner of BIO-IB, a life science boutique investment bank in New York. Prior to 2003, Beth was Managing Director and Co-Head of Global Capital Markets at ING Barings, shortly after their acquisition of Furman Selz LLC, where she founded and led its international institutional equity group for over 7 years. While at ING and Furman, she originated and executed many public and private financings for a wide variety of issuers throughout Asia, including the largest 144A equity offering for a real estate company in the Philippines (Empire East Land’s $210MM initial public offering). She started her career at Prudential Securities where she founded the international institutional equity business, and later headed the same product execution group at both Morgan Stanley and Lehman Brothers.

In the corporate sector, Beth was most recently Senior Vice President for Laureate Education Inc. (NASDAQ: LAUR), a $3 billion market cap company in the education sector. She worked across all business units in a corporate development role with a distinct focus on identifying and executing on opportunities in China. Notable transactions included exploring alternatives for Wall Street Institute (a company owned by Laureate and later acquired by the Carlyle Group); initiating and executing a joint venture with Jinjiang Group, the largest hotel group in China; and finding new acquisition and development opportunities for Les Roches, Laureate’s hotel management training business based in Crans Montana, Switzerland.

Beth received an MBA from American University in Washington, DC in conjunction with the School of Foreign Service, a BA, cum laude, from Boston College, and also studied at the Centre d’Etudes Internationale in Geneva, Switzerland.

Beth serves as Vice Chairman of the Friends of the Budapest Festival Orchestra Board, Director of EF Foundation, Global Ambassador for Susan G. Komen Foundation and Director of William J. von Liebig Medical Research Foundation.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Carlton Brown, Founder and Chief Executive, Immune Targeting Systems

Carlton Brown is CEO of Immune Targeting Systems (ITS; UK) and has a commercial background in life sciences. He qualified as a veterinarian in 1986 (Massey University, NZ) and obtained his MBA from The London Business School in 1997. Carlton is cofounder of ITS and co-inventor of the DepoVaccine T-cell vaccine platform. Since founding ITS Carlton has raised £14.5m of funding and led the Company’s development from an in-silico concept to a clinical based company. Prior to ITS he worked for SEDAC Therapeutics as commercial director and then COO, Dresdner Kleinwort Wasserstein as a marketing analyst, Cortecs Plc as corporate development director, Smithkline Beecham in strategic product development as an analyst and has been involved in a number of other bioentrepreneurial activities.

Stephanie Léouzon, Independent Consultant

Stephanie Léouzon is an independent consultant providing advice to life science companies. She is currently a member of the Board of Directors of the French biotech company Endotis SA, and serves as a Senior Advisor to Torreya Partners, a life sciences boutique advisory firm. Previously she worked in Health Care Investment Banking in the US and Europe from 1989-2010, most recently at Credit Suisse as a Managing Director and Senior Advisor. She has advised life sciences clients on more than 20 strategic transactions, valued at over $65billion, and been involved in over 45financing transactions to provide over $10 billion to health care clients.

Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985.

Philippe Dro, CEO, GlycoVaxyn

Philippe Dro joined GlycoVaxyn as Chief Executive Officer and member of the Supervisory Board in May 2008. He has 20 years entrepreneurial experience in the life science industry, including pharma, biotech and meditech companies.

Most recently, he was Chairman and CEO of Endoart SA, a medtech company developing telemetric driven implants for cardiac disease and obesity, that was sold to Allergan, Inc. From 1999 to 2003, Dr Dro was Chief Operating Officer (COO) and part of the founding team of AXOVAN AG, a GPCR focused drug discovery company, that grew the company to a clinical stage entity which was acquired by Actelion Ltd. Prior to this, he held the position of COO and director of the Board of Antares Pharma, Inc (AMEX: AIS), a drug delivery company formed by the merger of Permatec Group and Mediject, Inc. He also held executive director positions at Skyepharma Ltd during its listing on the LSE and in finance at Sandoz Pharma AG (now Novartis).

Dr Dro earned a Pharm D from University of Grenoble (France) and an MBA jointly from Ecole Supérieure de Comerce de Lyon (France) and Cranfield School of Management (UK).

Paul Higham, CEO, immatics biotechnologies GmbH

Paul Higham was appointed as CEO of immatics in August 2008. Previously, he served as Director Commercial Development at Ark Therapeutics Group plc where he was responsible for commercial strategy and all business development activities. In addition, he was in charge of establishing the operations and gene-based medicine production facilities of Ark Therapeutics in Finland.

Prior to joining Ark Therapeutics in 2001, Paul Higham worked as International Commercial Vice President for GI, Metabolic and Pain at GlaxoWellcome plc from 1996 to 2001, where he was responsible for all aspects of business development, strategic marketing, sales and finance. From 1985 to 1996, after completing his studies in Applied Biology, he held various sales and marketing positions of increasing responsibility with Bayer AG and eventually became General Manager of Bayer Pharmaceuticals for Sweden and Denmark.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Roel Bulthuis, Head, Merck Serono Ventures

Roel Bulthuis is Head of Merck Serono Ventures, the strategic venture capital group of Merck Serono. Through the ventures group, Merck Serono is committed to actively invest in emerging biotech companies which have the potential to provide innovative products in Merck Serono’s core therapeutic areas, or access to innovative technologies. Merck Serono Ventures also manages the Merck Serono Israel BioIncubator Fund. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before that, he worked at Devgen in Ghent, Belgium. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.

Stan Yakatan, Chaiman & Co-Founder, Katan Associates

After 30 years as a successful CEO, entrepreneur, and operational manager, Stan Yakatan has dedicated the last 12 years of his career to sharing his experiences with management teams interested in building technology based companies. His experience as a “C” level executive is far reaching he has served in such a capacity with:

New England Nuclear • EI Dupont • ICN Pharma • New Brunswick Scientific • Biosearch

These experiences have provided him with management skills and a corporate finance acumen that he enjoys sharing with others.

Stan has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany. In many cases he has also served as the initial CEO, and Chairman of these companies. In his career, he has advised several of the world’s leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA), and Biocapital (Canada). During the decade of the 1990’s Biocapital was the most successful venture capital fund in Canada.

Stan currently serves in a business development capacity for the XL TechGroup (AIM: XLT). The XL Tech Group systematically discovers unmet business needs, then creates, selects, and develops new technology businesses, and scales them to liquidity. Stan assisted XL TechGroup in the development of its business model, and advised on the overall capitalization strategy for XL Tech Group. In October 2004, XL TechGroup undertook an Initial Public Offering in connection with its listing on the Alternative Investment Market (“AIM”), raising in excess of $40.0 million.

Stan has completed and advised on numerous acquisitions and corporate finance transactions raising in excess of $1.0 billion dollars in the public and private capital financing markets. He is a frequent speaker at financial and biotechnology conferences throughout the world speaking on topics including, “Capital Raising for the Technology-Based Start-Up” and “The Need to be Global in the Quest for Capital and Partners”. Rick Biondi, Editor of Lab Business Magazine stated,” Mr. Yakatan is a venture capital raising Guru and it is part of his genetic make up.”

Stan is currently the Chairman of Grant Life Sciences, Inc., (OTCBB:GLIF) a company developing a revolutionary test for the screening of cervical cancer. Stan is also a member of the Board of Directors of Biophan, Inc. (OTC.BB). Stan serves as the strategic advisor to the State Government of Victoria, Australia. Stan is also the Executive Director and Chairman of Biocomm, in Melbourne, Australia, the first of its kind regional business development agency and early-stage capital pool. Stan currently sits on the Board of Mercury Therapeutics, Inc. which is developing new drugs for diabetes and obesity, and Phenomenome Discoveries, Inc., a novel biomarker company.

Christian Zahnd, CEO, Molecular Partners AG

Christian Zahnd (Switzerland) is Chief Executive Officer and member of the board of directors of Molecular Partners. After graduating with a master of science from the ETH Zurich and working for Merrill Lynch, Christian Zahnd earned his PhD from the University of Zürich. His main interest was on antibodies and antibody fragments, which he studied in own research and in academic and industry collaborations. Pioneering therapeutic applications of DARPins, he co-founded Molecular Partners and was a member of the management from the early days.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Eyal Baror, CEO, Neuronix Medical.

Mr. Baror serves as Neuronix CEO as of Summer of 2009. Eyal brings over a decade of experience in R&D and in executive-level positions in several medical devices companies. Mr Baror is a graduate of the prestigious Israel Defense Force’s Talpiot program, and holds a BS in Physics (cum-laude) from the Hebrew University of Jerusalem, and a MS in Physics (summa cum laude) from the Tel-Aviv University.

Margaret Beer, Senior Director, Scientific Liaison, Licensing and External Research, Europe, MSD

Margaret Beer studied at the Universities of Reading and London before carrying out her research work on serotonin pharmacology. She joined Merck, as a bench neuroscientist, in 1984 following her return to the UK from Stanford University.

She is one of the founding members of the team responsible for the development of Merck’s anti-migraine drug MAXALT and was involved in the project during the basic research stage through to the launch in 1997. Her other main areas of research interest include depression, anxiety and multiple sclerosis.

Margaret joined Merck’s Worldwide Licensing and External Research, Europe, group in 2003. This group was established in 2002 specifically in recognition of the scientific excellence in Europe and the wealth of potential licensing opportunities. Margaret assumed leadership of the group in 2008.

She is the co-author of 100 original research articles, review articles, and abstracts, and has presented widely at international professional meetings.

Holger Neecke, Director Business Development and Investor Relations, MolMed S.p.A.

Holger Neecke is Director of Business Development & Investor Relations at MolMed S.p.A., a clinical-stage biotech company developing novel therapies against cancer and listed on the Milan Stock Exchange.

He joined MolMed in October 2001. He has acquired a broad expertise in biotech business development, particularly by:• structuring, negotiating and finalising all contracts (research, license, collaboration, clinical trials, services) above €10’000,

including important license agreements with research institutions and pharma/biotech companies in Europe, Japan and the U.S.

• assessing market potential of products and performing DCF-based portfolio analysis• leading the project management of clinical-stage products

Since 2007, Holger Neecke is also responsible for MolMed’s Investor Relations, representing the company in roadshows and at investor meetings, and defining the annual IR communication plan.

Since 2004, he is lecturer of a 16-hours course in Business Strategy at the Univerisity “Vita-Salute San Raffaele” School of Medicine (course in Medical and Pharmaceutical Biotechnology).

Before joining MolMed, Holger Neecke worked at Biopolo Scrl, a biotech transfer agencies in Milan, where he developed and evaluated business plans for start-up companies.

Holger Neecke holds a degree in Molecular Biology from the University of Basel, Switzerland, a PhD in Genetics from the University of Milan, and a MBA from SDA Bocconi Business School, Milan.

Alethia De Leon, Global BD&L, Head Search & Evaluation Neuroscience and Opthalmic, Novartis Pharmaceuticals

Alethia de Leon currently leads globally the BD&L search and evaluation efforts for the Neuroscience and Ophthalmics Business at Novartis Pharmaceuticals. Before this role, she was part of the Strategy team at Novartis Pharmaceuticals. Previously she worked as a Venture Partner for a Biotech VC, led Biotech investments for a private equity fund of funds and worked in various roles in R&D process development and BD&L in Therion Biologics, Biogen Idec and Bayer Corporation. She holds a B.S. and M.S. in Chemical Engineering/Biology from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. She has also performed research at the Biotechnology Process Engineering Center at MIT, as well as at the Department of Materials at ETH.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Alex Lewis, Director of Corporate Activities & Strategy, Oxford BioMedica plc

Dr Alex Lewis is an experienced consultant to the pharmaceutical and biotech industry with a background of over 24 years in medical research and drug development. Alex was appointed to Oxford BioMedica’s Board in April 2008 and was also Director of Transactions and Due Diligence at The Datamonitor Group until June 2009 when he became Director of Lewis Healthcare Consultants. Prior to this, he was Head of the Partnering and Due Diligence practice of Wood Mackenzie research consultants. Alex has also been involved in the provision of expert reports and technical advice for the initial public offerings and fundraising activities for biotech companies based in the US and Europe.

Isabelle Dubé-Côté, Director, Business Development, International Listings, NYSE Euronext

Ms. Dubé-Côté is a Director at NYSE Euronext, the leading global operator of financial markets and provider of trading technologies with exchanges in the US and Europe. Since joining NYSE Euronext, Ms. Dubé-Côté has been responsible for International Business Development, Client Coverage and Marketing for the group; both out of the New York and in Paris offices.

Prior to joining NYSE Euronext, Ms. Dubé-Côté worked in Corporate & Investment Banking at the National Bank Financial and at CIBC World Markets in Canada.

Ms. Dubé-Côté graduated from Concordia University with a B.Com degree in finance and completed an MBA at New York University.

Esteban Pombo-Villar, Head of Strategic Alliance Management EU, Novartis Pharmaceuticals

Esteban Pombo-Villar PhD CChem FRSC is Head of Alliance Management at the Novartis Institutes for BioMedical Reasearch (NIBR). His group is responsible for managing research and early development collaborations with academic and biopharmaceutical groups world-wide. Dr Pombo-Villar obtained his PhD in Organic Chemistry from the University of Warwick in the UK. After postdoctoral studies at the ETH in Zurich, he joined Sandoz Neuroscience Research in Basel in 1988, and worked on drug discovery projects as well as leading collaborative projects for investigation of emerging technologies. He was External Collaborations Manager for Neuroscience, and from 2003, was Head of Stategic Alliance Management based in Basel, Switzerland.

Anja König, Managing Director, Novartis Venture Funds

Dr. Anja König is active in Switzerland and Europe and also responsible for expanding the fund’s presence to Asia Pacific. Before her appointment to the Novartis Venture Fund she held the position of assistant to the Chairman and CEO of Novartis.

Prior to joining Novartis she was an Associate Partner at McKinsey & Co., a global consultancy, where she worked with companies in health care, pharmaceuticals, and biotech in the US, Europe and Emerging Markets. Anja König is a scientist by training and holds a PhD in physics from Cornell University.

Chris Herr, Managing Director, Oxford Finance

Mr. Herr has been a member of Oxford’s business development team since 2002. He is responsible for business development for life sciences and healthcare services companies worldwide. Before joining Oxford, Mr. Herr established the Southwest operations for Charter Financial, which provided debt capital to venture-backed, life sciences companies. Previously, he had been co-founder and executive vice president of Coghill Capital Management. He has taught numerous public seminars as well as lectured at Penn State University on the topics of equity investing, portfolio management and estate planning. He is currently a board member on several privately held companies. Mr. Herr holds a B.A. in Liberal Arts from Pennsylvania State University and an M.B.A. from the London Business School.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Tim Sharpington, CEO, Phytopharm

Tim joined Phytopharm as CEO in July 2010 with more than 20 years experience in the pharmaceutical and biotech arena. Past companies include Pfizer, Sequus Inc, Arakis and Serentis. A clinical development professional by background, Tim has held leadership positions in private and public companies in both the US and Europe. He has led public and private fund-raising rounds, a number of M&A and product licensing deals and has led a number of products through development to registration. In addition to his position at Phytopharm Tim is a Non-Executive Director with Clinical Force, a clinical trials software company, and advises a number of small, emerging companies.

Florian Schodel, CEO, Philimmune LLC

Florian Schödel is the founder of Philimmune LLC, a consulting firm which provides strategic advice in the development of biologics, vaccines and pharmaceuticals.

Florian has > 20 years of successful experience in leading teams in the development of vaccines and biologics in the pharmaceutical and biotech industry and in academia.

His passion is preventative medicine and the use of modern science and technology for the improvement of public health – especially in the development of preventative and therapeutic vaccines and biologics.

Florian has a track record in running scientific and operational organizations, in business and strategic planning, for forming international strategic partnerships and alliances, in target identification and in all steps of clinical and pre-clinical development.

He has directed the design and execution of clinical studies for licensure and routinely interacts with international and national regulatory agencies. Florian has led the clinical teams responsible for several successful vaccine filings. A physician and microbiologist by training, Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories before he founded Philimmune.

Florian graduated in medicine at the Technical University, Munich, and earned doctorates in Transplantation Immunology and Medical Microbiology (Dr. med. Dr. med. habil.) from the University of Munich (LMU). He holds adjunct faculty appointments at the LMU and at the Biodesign Center of the ASU. Florian’s research at the Max-Planck Institute for Biochemistry, at Scripps, WRAIR and INSERM focused on hepatitis B and on novel recombinant vaccines against diseases such as hepB, malaria and typhoid.

Florian joined Merck Research Laboratories in 1996 as Director Clinical Vaccine Research leading EU vaccine clinical trials and the clinical development of rotavirus, measles, mumps and rubella vaccines. As the clinical liaison to an EU joint venture (SP-MSD) he participated in the development of pediatric combination vaccines.

Evert Kueppers, CEO, Pevion Biotech AG

Before joining Pevion in Fall 2010, Evert Kueppers was CEO of Pieris AG, an alternative protein scaffold biotech company based in Munich that he successfully restructured and refinanced by raising in total over USD 45 million from leading international/US investors. Prior to Pieris, he played, as Head of Business Development, a pivotal role in the corporate development of liposome drug delivery biotech IDEA AG by signing the largest German licensing deal in 2003 with Johnson & Johnson. This corporate deal laid the basis for its Series D financing round and the successful exit of its key investor, MPM Capital. Before joining the biotech industry, Mr. Kueppers worked four years for BASF Pharma (now Abbott Laboratories.) in International Operations (both at its German headquarters and Argentine subsidiary) and was a management consultant with the global pharmaceutical / health care team of AT Kearney in London, UK. Mr. Kueppers holds an M.S. degree in Biomedical Sciences from Leiden University, The Netherlands, and an MBA from RSM/Erasmus University, The Netherlands. He currently serves on the Board of Cenix Bioscience, Dresden, Germany.

Jan Öhrström, CEO, ProFibrix Inc

Jan Öhrström, MD is CEO and President of ProFibrix BV. Dr Öhrström has 20+ years biotech industry experience from companies in EU and the US. He started his career at Novo Nordisk A/S in 1990 and held various positions of increasing seniority within Development and Business/Marketing in Denmark and the US. Dr Öhrström joined the Senior Management Team at ZymoGenetics Inc in Seattle in 2000, and was actively involved in taking the company public (Nasdaq:ZGEN) in 2002 and was responsible for establishing the company’s development and business infrastructure. During his tenure at ZymoGenetics Inc, the company submitted its first BLA (RecoThrom©) that was approved in 2008. Dr Ohrstrom joined ProFibrix in 2008 and incorporated the company in the US same year. In 2011 he was promoted to CEO and is overseeing the US and Dutch operations of the company. He is an MD from University of Copenhagen and completed 6 years of clinical practice prior to joining the industry.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Guy Claude, Vice President Out-licensing and Special Projects Sanofi

Joined Pharmuka in 1980. Moved to Rhône-Poulenc Santé’s Licensing Department in 1984. Appointed Vice-President Business Development and Licensing of Rhône-Poulenc Rorer, based in Paris, in 1994. Became Deputy to Head of BD and Licensing of Aventis in 2000, heading the Corporate Licensing Teams based in Europe.

In his current position, Guy is responsible for the setting up of Out-Licensing deals or other appropriate and creative forms of Collaboration, with the objective of generating long term value for Sanofi and its Partners.

During his career in Business Development, he has been driwing negotiations, and/or managing, many Licensing deal as well as other forms of partnership.

Guy graduated from Business School in France and the UK. Born 1955, he is married and is the father of one son.

Sascha Bucher, Corporate Business Development, Roche

Sascha Bucher is based in Basel, Switzerland, and Deputy Head of Group M&A. In his role he is responsible for strategic mergers and acquisitions as well as divestments across the Roche Group.

Having spent over 10 years at Roche Corporate Business Development Sascha has been leading a number of international M&A transactions many of which included early stage biotech and diagnostics companies and technologies including the recent acquisitions of BioImagene (USD 100 mio), Medingo (USD 200 mio incl milestones), Marcadia Biotech (incl USD 500 mio incl. milestones) as well as PVT Probenverteilungs GmbH (EUR 85 mio incl milestones).

Trained as an economist, Sascha is a Certified European Financial Analyst and Harvard alumni. Before joining Roche Corporate Business Development he has worked in several finance positions and in banking.

Carole Nuechterlein, Head of Roche Venture Fund, Roche Venture Fund

Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel. Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. Due to her background in M&A, Carole led the negotiation team for the Roche acquisitions of GlycArt and Therapeutic Human Polyclonals. She currently serves as a board observer at Aileron, Alios, Ambit, Ambrx, Conatus, Envoy, Idaho Technology and Nereus. She has a BA from Valparaiso University and a JD from University of Michigan. More information on the Roche Venture Fund can be found at www.venturefund.roche.com.

Gary Jacobson, Executive Vice President and Chief Financial Officer, Ricerca Biosciences

As the executive vice president and chief financial officer for Ricerca, Gerald “Gary” Jacobson is responsible for the financial, legal, human resources, facilities and IT aspects of Ricerca.

He previously served as executive vice president and chief financial officer of Harlan Sprague Dawley, Inc., chief operating officer of Harlan Europe, senior vice president and division manager of LaSalle National Bank and senior vice president of new business development at American National Bank.

Mr. Jacobson is a graduate of Knox College in Galesburg, Illinois, and holds a certificate in political economy from the Adam Smith School of Economics in Glasgow, Scotland. He received his MBA from Marshall University in Huntington, West Virginia.

t back :: next u

Speakers




VC PARTNERW

ELCOME

SPONSORS

Joanna Horobin, President & CEO, Syndax Pharmaceuticals, Inc.

Joanna Horobin MD is President and CEO of Syndax Pharmaceuticals, a privately held company focused on the development of innovative cancer therapies. Formerly Vice President of Oncology at Rhone-Poulenc Rorer (now Sanofi) and Chief Operating Officer of CombinatoRx, Inc., Dr. Horobin has more than 25 years of pharmaceutical drug development experience in multiple therapeutic areas, with a focus on oncology and a particular interest in the development of combination strategies.

At Rhone-Poulenc Rorer she led the global oncology business, including directing the successful global launch, and subsequent market expansion, of Taxotere® (docetaxel) and also led a successful joint venture with the Japanese company Chugai, Chugai Rhone-Poulenc, which developed and launched the granulocyte growth factor Granocyte® (lenograstim) for the European market. As Chief Operating Officer at CombinatoRx, a company focused on combination products, she raised over $70 million in private financing, transitioned the company from a discovery-focused start-up to a clinical-stage enterprise, and positioned the company for a successful initial public offering. Dr. Horobin was also Executive Vice President at EntreMed, a company developing angiogenesis inhibitors. She spent a year as Entrepreneur in Residence with the venture capital firm MPM Capital.

Her pharmaceutical experience spans clinical development, marketing, and general management in both public and private companies.

Dr. Horobin qualified in medicine from the Victoria University of Manchester, England, and additionally gained Membership of the Royal College of General Practitioners in the United Kingdom. She holds the Diploma of Pharmaceutical Medicine from the Royal College of Physicians in the United Kingdom.

Klaus Schollmeier, CEO, Santhera Pharmaceuticals

Klaus Schollmeier is Member of the Board of Directors and Chief Executive Officer of Santhera. Mr Schollmeier joined Graffinity Pharmaceuticals AG as CEO in 2003 and became CEO of the Company when Graffinity and MyoContract AG were combined to form Santhera in 2004. Prior to joining the biotechnology industry in 2003, he served as managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Prior to that, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included head of oncology/immunology research at BASF’s central laboratories in Ludwigshafen, Germany, and senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, US (1989 to 1993). His business functions included general manager of BASF Pharma Netherlands from 1996 to 1998 and vice president and general manager for Western Europe thereafter. From 1994 to 1995, he led BASF’s acquisition and integration of Boots Pharmaceuticals. Mr Schollmeier holds a PhD in biology from the University of Düsseldorf, Germany, and in 1991, he became an adjunct research associate professor at the Boston University Medical School, Massachusetts.

Rob Woodman, Principal, Sofinnova Partners

Rob Woodman joined Sofinnova in January 2007. Prior to Sofinnova, from 2005 – 2006, Rob worked in the Business Management team at Cancer Research Technology Ltd, an oncology focused technology transfer and development company in the UK, and in 2004 was a Business Analyst in the Management Consultancy Group of pharmaceutical information source IMS Health, also in the UK. Rob holds a PhD in Molecular and Cellular Biology / Oncology from the University of Cambridge and an MSc in Biochemistry from the University of Oxford. Inventions made during the course of Rob’s PhD were patented; this IP is now part of the foundations of a biotech company. His research was published in peer reviewed journals.

Speakers




VC PARTNERW

ELCOME

SPONSORS

t back :: next u

Eduardo Bravo, CEO, TiGenix

Eduardo earned his degree in business administration at the CUNEF(Madrid, Spain) and also holds an MBA from INSEAD (Fontainbleu, France).

He brings more than 20 years of experience in the pharmaceutical industry, during which time he held several senior management positions. He was previously Vice President for Latin America at Sanofi-Aventis, where he was responsible for over than 2,000 employees and more than €1 billion in sales. At Sanofi-Aventis he also held the positions of Marketing and Sales Manager for Europe and General Manager in Belgium. Eduardo also worked for 7 years at SmithKline Beecham in both national and international commercial roles.

In July 2005 he joined the Genetrix Group as Managing Director, and subsequently in 2006, was appointed CEO of Cellerix where he was also a member of the Board of Directors. Cellerix was a biopharmaceutical company founded in 2004 as a spin-off from the Genetrix Group and focused on the development of innovative cell therapies.

He was appointed CEO of TiGenix NV in May 2011 following a business combination of Cellerix and TiGenix to create a new European leader in the field of cell therapy, and is a member of the TiGenix Board of Directors.

Lukas Guenther, Principal, Life Science Team, Wellington Partners

With an international background in clinical medicine and economics, Lukas has an excellent foundation for identifying the most promising investment opportunities. He joined Wellington in 2007 as a Principal in the Life Science team and focuses primarily on deal flow management and due diligence processes.

Prior to joining Wellington, Lukas had worked for six years as a surgeon and clinical researcher specialising in organ transplantation at the department of surgery at the Universities of Heidelberg and Freiburg. From 2000 to 2002, Lukas was a post-doctoral scientist at Harvard University in Boston, where he conducted research in the fields of immunology and protective genes. In 2003/2004, Lukas also completed a fellowship in clinical islet transplantation at the University of Minnesota in Minneapolis participating in NIH multi-centre trials.

Lukas studied Medical Sciences in Berlin and Cape Town. He holds a doctorate in Medicine from the Humboldt University Berlin and a Global OneMBA degree from RSM Erasmus University, Rotterdam.

Melanie Lee, Chief Executive Officer, Syntaxin

Melanie Lee’s academic grounding in molecular genetics in three complex systems of DNA repair and recombination, RNA splicing and cell cycle was a broad and an important foundation for her future career. Melanie was cited by Sir Paul Nurse in his inaugural ceremony in Stockholm on receipt of his Nobel Prize for Medicine in 2001 for her contribution to his cell cycle work. Melanie’s industrial career has been through Glaxo, GlaxoWellcome, Celltech and UCB. During her career leading the discovery organization as well as Research & Development, for 6 years as a Board Director with Celltech plc and 5 years on the Executive Committee of UCB, Melanie has led R&D through 6 integrations. In 2008 she put in place the foundations of an innovative organization named UCB NewMedicines which is accountable from Discovery through to Proof of Concept for small and large molecule drugs. Melanie is the Chair of Cancer Research Technology and Deputy-Chair of Cancer Research UK. Melanie was honoured in 2008 with a CBE for services to Medical Science.

Melanie believes that the pharmaceutical industry is undergoing a complete change of mindset and skills base as well as way of working which enhances the importance of biotech companies for the future of the new drug Research & Development. She believes that the importance of academia and industry (large & small) working together is crucial to innovation and advancing science and human health. Melanie is currently CEO of Syntaxin Ltd which she joined in February 2010.

Graeme Martin, President & CEO, Takeda Research Investment

Dr. Martin is President and CEO of Takeda Ventures, Inc. (TVI) with day-to-day responsibility for operations. With more than 30 years of pharmaceutical R&D experience in the Pharmaceutical and Biopharmaceutical industry (Wellcome; GlaxoWellcome: Hoffman La Roche; Telik), he joined Takeda in 2003 and has been instrumental in building the Company’s strategic venture operations based in Palo Alto, California. Dr. Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK.




VC PARTNERW

ELCOME

SPONSORSt

back :: next u

Affimed Therapeutics AG www.affimed.com

CONTACTSDr. Florian Fischer Chief Finance Officer

Daniela Treiber / Claudia Heisch Assistants

ADDRESSAffimed Therapeutics AG Im Neuenheimer Feld 582 69120 Heidelberg

TELEPHONE+49 6221/65307 0

FAX+49 6221/65307 77

EMAIL [email protected]

Assistant: [email protected]@affimed.com

YEAR FOUNDEDAffimed was founded in 2000 in Heidelberg as a spin-off from the German Cancer Research Centre (DKFZ), Heidelberg, and employs 28 people.

FINANCIAL SUMMARY

We are backed by a peer group of investors including Orbimed, Aeris, LSP, BioMed Invest and Novo Nordisk A/S.

We are currently raising 25M€€ in a Series D financing for the outlined clinical development.

COMPANY PROFILE

Affimed is a clinical stage therapeutic antibody company developing TandAbs as novel and improved treatments in oncology. TandAb molecules are bi-specific human antibodies with excellent targeting efficacy and product stability. TandAbs possess increased therapeutic potential compared to monoclonal antibodies. Robust GMP production and downstream processes have been established. In pre-clinical Tox studies, TandAbs show an excellent safety profile and its first product has entered clinical trials in 2010.

Affimed´s lead product candidates comprise:

• AFM 13 for the treatment of Hodgkin’s lymphoma has entered clinical studies in 2010. So far there were more than 15 patients treated. The product appeared to be safe and well tolerated.

• AFM 11 for Non-Hodgkin’s lymphoma is currently in late stage preclinical development.

Development strategy: We are planning to finalize the ongoing study in 2012 and to further develop AFM 13 in a pivotal Phase IIb study for 3rd line treatment (finalized in H1 2014). We are furthermore seeking co-development partners to conduct studies for 1st and 2nd line treatment of HD.

AFM 11 the product will be developed until clinical PoC (finalized in H1 2014).

MANAGEMENT Dr Adolf Höß, CEODr Rolf Günther, COOProf Dr Melvyn Little, CSODr Florian Fischer, CFO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Affitech A/S www.affitech.com

CONTACTSMartin Welschof Managing Director

Randi Krogsgaard

ADDRESSOle Maaløes Vej 3 DK- 2200 CPH N Denmark

TELEPHONE+45 3917 8259

Martin Welschof +47 95128237

Randi Krogsgaard +45 23201001

FAX+ 47 22 95 83 58

EMAIL [email protected] [email protected] [email protected]

YEARS FOUNDED2009 (Combination of Affitech Re-search AS Norway and Pharmexa A/S Denmark)

FINANCIAL SUMMARY

On 31st March, 2011 the Affitech Group’s total assets amounted to DKK 92,390 thousand. Cash and cash equivalents amounted to DKK 50,453 thousand on 31st March, 2011 In April 2010 Affitech completed a directed share offering which provided DKK 156.1 million in net new equity.

COMPANY PROFILE

Affitech discovers and develops drugs based on fully human antibodies for cancer, inflammation and other serious diseases where antibody therapeutics can be beneficial for patients. The Company’s discovery efforts utilize its fully integrated antibody expression repertoires, phage libraries and proprietary screening platforms both internally and in partnership with pharma and biotechnology companies.

Affitech A/S has built a substantial pipeline of early stage fully human antibody therapeutic drug candidates using the MBASTM and CBASTM screening platforms. Lead compound AT001/r84 is an anti-VEGF antibody that inhibits VEGF binding to VEGFR2 while interaction of VEGF with VEGFR1 remains unharmed. AT001/r84 and the Company’s first GPCR targeted antibody program AT008/anti-CCR4 are currently being developed in collaboration with Russian Biotech partner IBC Generium.

MANAGEMENT

Martin Welschof, Managing DirectorAlexander Duncan, Chief Science OfficerStig Jarle Pettersen, Chief Financial Officer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Akers Biosciences, Inc www.akerbiosciences.com

CONTACTMr Thomas A. Nicolette President and Chief Executive Officer

ADDRESSAkers Biosciences, Inc. USA 201 Grove Road Thorofare, New Jersey 08086

UK212 Piccadilly London W1J9HG UNITED KINGDOM

TELEPHONE+1.856.848.8698 USA +44.20.7917.9476 UK

FAX+1.856.848.0269 USA


YEAR FOUNDED1989

FINANCIAL SUMMARY – 2010

– Revenue increased 72% to $3.1 million (2009: $1.8 million) – Gross Profit Margin increased by 18 basis points to 57.8% (2009: 40.3%)– Adjusted Loss Before Tax substantially reduced by 74% to $1.2m (2009 loss: $4.6 million)– EBIDTA increased by 84% to loss: $649k (2009 loss: $4.1 million)– Company is debt free with current assets in cash and cash equivalents at year-end of $423k (2009: $2.6

million)– Cash position subsequently increased by the £2.16 million placing in February 2011

COMPANY PROFILE

ABI was founded in 1989 in the United States and gained admission to AIM of the London Stock Exchange in 2002. The Company’s 6 proprietary platform technologies merge scientific innovation with user-friendly formats to deliver cost-effective and time-efficient testing solutions where and when they’re needed. 2010 was a very productive year for ABI’s new product pipeline. Moving into 2011, ABI is well-positioned to complete the clinical development of a number of novel rapid diagnostic testing solutions and introduce these products into high value markets, towards the end of the year and beyond.

MANAGEMENT

Senior ManagementThomas A. Nicolette, President and Chief Executive OfficerRaymond Akers, Jr., PhD, Executive Vice ChairmanGary Rauch, Corporate ControllerLee Meyers, Vice President, OperationsPatrice Laterra McMorrow, Vice President, Marketing

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

AM-Pharma B.V. www.am-pharma.com

CONTACTSErik van den BergChief Executive Officer

Raffaella BalenaAssistant

ADDRESSAM-Pharma B.V. Rumpsterweg 6 3981 AK Bunnik The Netherlands

TELEPHONE+31-30-2289222 cell: +31.6.11646554

FAX+31-30-2289220


assistant:[email protected]

YEAR FOUNDED2002

FINANCIAL SUMMARY

C-round 2007: €7M

D-round 2011: ~ €29M

COMPANY PROFILE

AM-Pharma is developing recombinant human Alkaline Phosphatase for treatment of Acute Kidney Injury (iv) and severe Ulcerative Colitis (oral)

Alkaline Phosphatase (AP) is being developed as an intravenous solution for the treatment of acute kidney injury (AKI).

AKI is a condition that affects 2 million patients annually and kills nearly 700,000 annually. There is no therapeutic approved for the treatment of AKI.

Clinical data from two independent phase-II studies demonstrates that treatment with AP reduces the need for dialysis compared to the placebo group with a factor two. AP would be the first drug on the market to treat AKI. Also a significant improvement in patient condition was observed in the treatment group.

In an open-label Ulcerative Colitis study, orally administered Alkaline Phosphatase demonstrated similar efficacy as infliximab. Measured with the Truelove-Witts score AP showed 79% response and 26% remission rate at week 9.

The company is now switching from bovine AP to a recombinant AP source. Thereafter further clinical studies will be conducted to establish proof-of-concept with the recombinant human AP.

AM-Pharma has a solid patent portfolio consisting of multiple ‘method-of-use’ and ‘composition of matter’ patents.

MANAGEMENT

Senior ManagementErik van den Berg, CEOJacques Arend, VP Clinical Development Steve Connor, VP PreClinical & Manufacturing

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Amakem NV www.amaken.com

CONTACTSDr Jack Elands Chief Executive Officer

Dr Dirk Leysen Chief Scientific Officer

ADDRESSAmakem NV BioVille Agoralaan A bis Diepenbeek, B-3590 Belgium

TELEPHONE+32 474 828-580

FAX+32 11 490-209


YEAR FOUNDED2010

FINANCIAL SUMMARY

Seed financing of 1.5M€ in 2010 to establish proof of concept of the Localized Drug Action platform focused on the development of ROCK inhibitors for the treatment of COPD and inflammatory eye diseases.

18M€ series A investment to develop AMA0076 for glaucoma. to clinical proof of concept.

Series A investors: Forbion, Crédit Agricole Private Equity, Vesalius BioCapital, LRM, Vinnof/PMV, Life Science Research Partners.

COMPANY PROFILE

Amakem is an ophthalmology company developing new treatments for serious eye conditions. Amakem’s product pipeline is based on its unique Localized Drug Action platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects. Amakem’s lead candidate, AMA0076, is developed for the treatment of glaucoma. The Company is working to apply the Localized Drug Action platform to a range of eye diseases.

AMA0076 is a novel, highly potent Rho Kinase (ROCK) inhibitor targeted at the treatment of glaucoma, a condition resulting in vision loss and ultimately blindness. AMA0076 has been designed to allow for high localized dosing in the eye combined with low systemic exposure, resulting in a lack of side effects.

AMA0076 has been shown in a number of models to be highly effective in reducing intraocular pressure (IOP), a major factor in glaucoma, by increasing outflow through the trabecular meshwork. AMA0076 has also been shown to avoid important side effects such as hyperemia which is distressing for patients and has been a dose limiting factor for other ROCK inhibitors in development. Also known as ‘red eye’ hyperemia results from excess blood flow in vessels in the white of the eye.

Amakem’s primary focus is on eye diseases. As well as glaucoma, the Company is exploring the development of additional compounds targeting other eye diseases and has collaborations with amongst others the Ophthalmology Research Center of the University Leuven Hospital (ULH) on several other ophthalmic indications.

In addition to AMA0076 in glaucoma, Amakem has demonstrated proof-of-concept in advanced models of Chronic Obstructive Pulmonary Disease (COPD) and asthma.

Amakem was founded in 2010 and is based in Diepenbeek, Belgium.

MANAGEMENT Senior ManagementJack Elands, CEODirk Leysen, CSO

Board of DirectorsMichael Palfreyman, chairmanChristina Takke, (Forbion) Emmanuelle Coutanceau, (Crédit Agricole) Gaston Matthyssens, (Vesalius) Nico Vandervelpen, (LRM) Jack Elands Dirk Leysen

Scientific AdvisorsIngeborg Stalmans, University Hospital Leuven Désiré Collen, founder Thrombogenics Gary Novack Eric Sheinin Bob Osterberg Thomas Brown

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

AMT (Amsterdam Molecular Therapeutics) www.amtbiopharma.com

CONTACTJorn Aldag Chief Executive Officer

ADDRESSAMT Meibergdreef 61 1105 BA Amsterdam

TELEPHONE+31 20 566 8014

FAX+31 20 566 7292

EMAIL [email protected] [email protected]

YEAR FOUNDED1998

FINANCIAL SUMMARY

€ M 2009 2010

Income 0.3 1.4

Net Result (17.2) (19.1)

Cash 22.6 17.9

COMPANY PROFILE

AMT, founded in 1998 and based in Amsterdam, is a leader in the development of human gene based therapies. Using AAV as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. This safe and efficacious proprietary platform offers a unique manufacturing capability which can be applied to a large number of rare (orphan) diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with several AAV-based gene therapy products in LPLD, Hemophilia B, DMD, Acute Intermittent Porphyria and Parkinson’s Disease at different stages of research or development.

AMT has established a safe and effective gene delivery approach and a unique process that enables the economical, commercially scalable manufacturing of gene therapy products. This powerful platform combined with the research expertise of our collaboration partners provides AMT with exciting opportunities to deliver more curative therapies to patients faster

MANAGEMENT

Jorn Aldag, CEO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Anergis SA www.anergis.ch

CONTACTVincent Charlon PhD, CEO

Zoltan Czigler MBA, Finance Director

ADDRESSBioPole III Route de la Corniche 9B CH-1066 Epalinges Switzerland

TELEPHONE+41 21 651 9220

FAX+41 21 651 9221


YEAR FOUNDED2001

FINANCIAL SUMMARY

CHF 18M round March 2011.

COMPANY PROFILE

ANERGIS SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel ultra-fast specific immunotherapy (also known as “SIT” or “desensitization”) products. Allergy is the most prevalent and the fastest growing chronic condition in the industrialized world with over 300 million people affected. Current SIT remains underused due to its long duration (3-5 years of treatment) and safety risks. ANERGIS develops ultra-fast and safe SIT treatments for allergic patients, which can achieve induction of tolerance to the allergen in few injections only. ANERGIS possesses a unique know-how and the exclusive rights to the technology of Contiguous Overlapping Peptides (“COPs”) developed jointly by the University of Lausanne, Switzerland (UNIL), the Federal Institute of Technology (EPFL) and the Centre Hospitalier Universitaire Vaudois (CHUV). Because ANERGIS COPs are long peptides they present the advantage of being recognized and processed by the antigen presenting cells of the immune system using similar mechanisms as the original allergen. This feature, combined with the fact that the COPs reproduce –in separate molecules- the full amino acid sequence of the allergen, and that overlapping sequences guarantee that all linear epitopes are present, ensures the high immunogenicity of the COPs. In the past years, ANERGIS has studied proprietary COPs targeting bee venom and birch pollen allergies both in animals and in humans. These studies have confirmed the excellent safety (no immediate allergic reaction) and expected immunogenicity (production of specific antibodies and cytokines against the original allergen) of ANERGIS COPs.

MANAGEMENT

Vincent Charlon, CEO20+ years global clinical development and management experience • LS Pharma International, CEO• Hesperion, CEO• Hoffmann-La Roche, Clinical Director

Christophe Reymond, CSO20+ years biology, immunology, patents and start-up experience • Anergis, CSO/COO• Dictagène, CSO• Assist Professor University Lausanne

François Spertini, Medical Expert20+ years medical practice and research in immunology and allergy • Assoc. Prof. and Chief Allergy/Immunology• Lausanne University Hospital (CHUV)• Founder of Anergis

Zoltan Czigler, Finance Director MBA Insead, MSc • Business and Finance consultant • Director Finance Kuros Biosurgery AG • Investment and finance manager, VI Partners

Jean-Paul Rohmer, Business Development20+ years biotech, pharma business and commercial management• IDEFI Gestion, Managing Director• Stallergenes, GM & CEO• Eli Lilly France, Head Pharma Division

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Antisense Pharma GmbH www.antisense-pharma.com

CONTACTSDr Guenter Auerbach Head Business Operations

Dr Stefanos Theoharis Senior Director Corporate Development & External Research

ADDRESSJosef-Engert-Str. 9 93053 Regensburg Germany

TELEPHONE+49 941 92013 0

FAX+49 941 92013 29


YEAR FOUNDED1998

FINANCIAL SUMMARY

Successful closing of financing round with MIG Fonds and GA Global Asset Fund in 2011.

COMPANY PROFILE

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany.

The company focuses its innovative strength on targeted cancer immunotherapies and is dedicated to discovering and developing drugs based on a powerful gene silencing technology for worldwide commercialization. The pipeline comprises the lead product trabedersen in clinical development for high-grade glioma, pancreatic carcinoma and malignant melanoma as well as drug candidates in discovery and preclinical development for cancer and other indications.

Trabedersen (AP 12009) specifically inhibits the synthesis of the human transforming growth factor beta 2 (TGFß2), a multifunctional cytokine promoting tumor malignancy via multiple mechanisms.

Antisense Pharma has a solid and long-lasting IP portfolio of granted patents in all major markets.

The EMA and the FDA have granted trabedersen an orphan drug status for high-grade glioma and pancreatic carcinoma.

RecentHighlights:Randomized, active controlled Phase III trial (SAPPHIRE) with trabedersen open for recruitment of patients with anaplastic astrocytoma and secondary glioblastoma.Encouraging survival and excellent safety of trabedersen in pancreatic cancer and malignant melanoma in Phase I/II trial..

MANAGEMENT

Dr Hubert Heinrichs, Acting Chief Executive Officer and Chief Medical Officer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

APEIRON Biologics AG www.apeiron-biologics.com

CONTACTSHans Loibner, PhD Chief Executive Officer

Lukas Kadawy, Mag. Chief Financial Officer

Manfred Schuster, PhD Chief Operating Officer

ADDRESSAPEIRON Biologics AG Campus-Vienna-Biocenter 5 1030 Vienna, Austria

TELEPHONE+43 1 8656577

FAX+43 1 8656577-800


YEAR FOUNDED2003 (operational since 2006)

FINANCIAL SUMMARY

Private company.

COMPANY PROFILE

Apeiron, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer and related conditions. On top of an innovative preclinical pipeline, Apeiron presently has one clincal phase III project and three projects in phase II. Apeiron’s business strategy is to generate value by applying its know-how to advance projects towards clinical proof of concept. Apeiron’s primary customers include all pharmaceutical/biotech companies active in the relevant disease areas. In certain cases, however, Apeiron may complete all development stages and market the final product directly.

MANAGEMENT

Hans Loibner, CEO, PhD in Organic Chemistry from the University of Vienna. More than 20 years in R&D management at Sandoz/Novartis; Founded and developed the biotech company Igeneon (cancer immunotherapy). Main responsibilities: business strategy, R&D strategy, public relations.

Manfred Schuster, COO, PhD in Biochemistry and Biotechnology from the University of Natural Resources and Applied Life Sciences in Vienna. Started his career at the Novartis Research Institute, Vienna; Worked as scientist and project leader at Igeneon. Main responsibilities: clinical research, QM, IP, IT, infrastructure, cooperations.

Lukas Kadawy, CFO, graduate degree in Commerce from Vienna University of Economics and Business. He has worked at IBM prior to joining Apeiron. Main responsibilities: finance, legal, investor relations, human resources, administration.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

APEPTICO GmbH www.apeptico.com

CONTACTUniv.-Doz. Dr. Bernhard Fischer CEO

ADDRESSAPEPTICO GmbH c/o mino bueros Mariahilferstr. 136 1150 Vienna Austria

TELEPHONE+43 664 1432919

FAX+43 1 25330337795


YEAR FOUNDED2008

FINANCIAL SUMMARY

2008: Pre-seed EURO 0.5 Million

2009: Round A EURO 3.5 Million

2010: Round B EURO 3.5 Million

COMPANY PROFILE

APEPTICO is a clinical stage biotech company in Vienna, Austria. We develop new peptide-based medicinal drugs for the clinical treatment of severe and chronic diseases. Our peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. All our products address highly profitable and growing markets.

We collect molecular, structural, biological & medical data of well-characterised proteins and biopharmaceuticals in our proprietary data base PEPBASE(TM). Identification of a bio-active moiety is the first step of PEPSCREEN(TM), our fast-track product development pathway.

The applications PEPSCREEN(TM) and PEPBASE(TM) in combination with our cumulated Research & Development experience enables to create novel compounds which allow for intellectual property protection, and facilitates lower clinical failure rates, at reduced costs and decreased business risks.

APEPTICO’s lead molecules of the AP301 family are synthetic peptides. AP301 is water soluble and can be administered into the lung by instillation or by oral inhalation. Formulated AP301 can be nebulised and the resulting aerosol is composed of peptide/water droplets of diameter 3 µm or less. AP301 was originally designed for the treatment of acute lung injury and acute respiratory distress syndrome. Additional research demonstrated that AP301 has additional significant potential in related clinical indications, such as prevention and treatment of edematous respiratory failure, pulmonary permeability edema, prevention of progression of acute hypoxemic respiratory failure due to bacterial / viral pneumonia and prevention of ischemia reperfusion injury. AP301 activates lung edema reabsorption and protects both endothelial and epithelial lung cells from influenza virus-, microbial virulence factor- and reactive oxygen species-induced lung edema and hyper-permeability of lung capillaries.

MANAGEMENT Dr Bernhard Fischer, CEOProf Dr Rudolf Lucas, CSO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Apricus Biosciences, Inc.www.apricusbio.com

CONTACTSDr Bassam Damaj Chairman, President & CEO

Ed Cox VP Corporate Development & IR

ADDRESS6330 Nancy Ridge Dr., Suite 103 San Diego, CA 92121 U.S.A.

TELEPHONEDr Bassam Damaj +858-222-8041

Ed Cox +858-222-8041


YEAR FOUNDED1987

FINANCIAL SUMMARY

NASDAQ: APRIShares Out: 19.6M*Fully-diluted Shs: 22M*Float: 16M*Cash position $10.2M*Share-price $5.26**Marketcap ~$105M**Ave. Daily volume ~320k**2010 Revenues ~$5M

*As of March 31, 2011, **As of June 24, 2011

COMPANY PROFILE

Apricus Bio, a San Diego based revenue-generating specialty pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.

Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.

MANAGEMENT Dr. Bassam Damaj, Chairman, President and Chief Executive OfficerSteve Martin, Senior Vice President and Chief Financial OfficerEdward Cox, Vice Corporate Development and Investor Relations Randy Berholtz, Executive Vice President, General Counsel and Secretary

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

biocrea Gmbhwww.biocrea.com

CONTACTSTom Kronbach, PhD CEO

Viktor Viehweg CFO

ADDRESSBio3 Research S.r.l. Via della Moscova 6/8 20121 Milano Italy

TELEPHONE+49 351 4043 0

Tom Kronbach, PhD +49 351 4043 3332

Viktor Viehweg +49 351 4043 0

FAX+49 351 4043 3216


YEAR FOUNDED2010

FINANCIAL SUMMARY

Private Company, initial funding by Biotie Therapies, which has a minority stake.

COMPANY PROFILE

biocrea is creating new therapies for debilitating CNS Diseases. The company is an MBO from Biotie Therapies Corp. (Nov. 2010). With a new Management Team from large Pharma and corporate finance biocrea strives to acquire projects and their development to major value inflection points through VC funding and will fund its discovery activities through non-dilutive funds.

We have a proven track record to turn concepts into candidate drugs and have been partnering with GSK, Wyeth and Pfizer.

MANAGEMENT

Tom Kronbach, Chief Executive OfficerMartin Gunthorpe, Chief Scientific OfficerViktor Viehweg, Chief Financial OfficerSimon Ward, Executive Vice President Chemistry & Development

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Biotie Therapies Corp. www.biotie.com

CONTACTSVirve NurmiHead of Investor Relations

Timo Veromaa Chief Executive Officer

ADDRESSBiocity Tykistökatu 6 FIN-20520 Turku Finland

TELEPHONE+358 2 274 8900


YEAR FOUNDED1992

FINANCIAL SUMMARY

Cash and cash equivalents and short term investments totaled EUR 40.9 million on 30 June 2011 (EUR 11.6 million on 30 June 2010). The groups’ financial position had been strengthened by a private placement of EUR 27 million in March 2011 and by the liquid assets of Synosia acquired in February 2011.

COMPANY PROFILE

Biotie is an international biopharmaceutical company focused on the development of innovative, clinically differentiated medicines to address unmet medical needs primarily associated with neurological and psychiatric diseases and with selected inflammatory diseases. We aim to develop treatments that will improve the lives of patients with conditions such as Parkinson’s and Alzheimer’s diseases, drug dependency and inflammatory liver diseases.

Our highly experienced development teams in Europe and the US are focused on efficiently delivering safety and efficacy data for our compounds. For niche indications Biotie will consider bringing products to the market by itself. For larger indications we will seek strategic partnerships with pharmaceutical partners for late-stage development and commercialization. Our current pharmaceutical partners include Lundbeck, Roche, UCB Pharma and Seikagaku Corporation.

Biotie’s most advanced product, nalmefene for alcohol dependence, has completed Phase 3 clinical development by licensing partner H. Lundbeck A/S.

MANAGEMENT

Timo Veromaa, President and CEOStephen Bandak, Chief Medical OfficerIan Massey, Chief Operating OfficerChris Piggott, Chief Business OfficerUlla Sjöblom, Chief Financial Officer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

C10 Pharma AS www.c10pharma.com

CONTACTSTorgeir Vaage CEO

Thorfinn Ege COO

ADDRESSC10 Pharma AS Drammensveien 41 0271 Oslo Norway

TELEPHONE+47-92405235

EMAIL [email protected] [email protected]@c10harma.com

YEAR FOUNDED2009

COMPANY PROFILE

C10 PHARMA is a Norwegian company focusing on the development of a new family of antibiotics in the macrolide class.

The basis for the development strategy is proprietary technology relating to post-synthetic modifications of the carbon-10 side chain in 14-membered macrolide molecules.

The company has shown that chemical modifications in this position of the macrolide ring can be used to build molecules with highly attractive antimicrobial and ADMET properties.

The company is currently in the lead generation phase of the project, based on structure-guided drug design. Test data are very promising – showing that the carbon-10 can be used to allow unprecedented structural modifications, both building attractive antimicrobial activity and modulating key ADME(T) characteristics.

The company expects to enter lead optimization phase late 2011, and the company is planning to raise funding sometime during 1H:2012. The main investors in the company are Novo Seed (Denmark) and Sarsia Seed (Norway).

MANAGEMENT

Torgeir Vaage, CEOPreviously CFO of SantoSolve, responsible for raising three financing rounds, and supporting the company from preclinical stage until phase III. He has extensive experience from the Nordic investment banking sector.

Thorfinn Ege, COOEge has extensive experience in research, business development and management in the pharmaceutical sector. Previously CEO in SantoSolve AS, advancing the company’s project from the early preclinical stage to phase III.

Sergio Lociuro, CSOLociuo has more than 20 years experience in antiinfectives and in drug discovery, from Arpida Ltd (Head of research) and executive mgmt. positions in MMD and GSK. He is author of numerous publications and holds several patents.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Caldera Health Limited www.calderahealth.com

CONTACTRoland Toder, PhD Vice President Business Development

ADDRESSCaldera Health Limited, P.O.Box 11664, Ellerslie, Auckland 1542, New Zealand

TELEPHONE+64-9-571 0310

FAX+64-9-571 0316


YEAR FOUNDED2009

FINANCIAL SUMMARY

In May, 2010, Caldera completed a seed investment of NZ$560,000. In June, 2010, the Company was awarded a NZ$189,000 Business Growth Grant from the New Zealand Foundation of Research, Science and Technology. In May, 2011 Caldera completed a first round of equity funding, raising NZ$987,500. A second research grant application is on its way.

COMPANY PROFILE

Caldera Health Limited is an Auckland-based, human in vitro Diagnostics (IVD) company. It is developing sophisticated molecular diagnostic devices for early detection of prostate cancer, superior to the globally used PSA test by improving reliability and indicating the long-term outcome of any cancer detected. The diagnostics will allow extensive monitoring of tailored treatments for prostate cancer, not possible today because of the limited molecular diagnostic tools available.

MANAGEMENT

James D. Watson, PhD, Chief Executive OfficerRichard L.S. Forster, PhD, Chief Science OfficerRoland Toder, PhD, VP Business Development

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Can-Fite BioPharma, Ltd. www.canfite.com

CONTACTSPnina Fishman, Ph.D Chief Executive Officer

Barak Singer VP Business Development

ADDRESS10 Bareket Street, Kiryat Matalon P.O.Box 7537, Petach Tikva 49170, Israel

TELEPHONE+972-3-924 1114

FAX+972-3-924 9378


YEAR FOUNDED2001

FINANCIAL SUMMARY

Can-Fite has raised till today approximately $60M from venture funding, public offerings on the Tel Aviv Stock Exchange (TASE) and from strategic partners.

COMPANY PROFILE

Can-Fite is an Israeli biopharmaceutical company with a rich pipeline of small molecule drugs in Phase 3 and Phase 2 clinical development stages. The platform technology utilizes the Gi protein associated A3 adenosine receptor as a target and a biological marker. The company has diverse pipeline of proprietary compounds, addressing inflammatory, ophthalmic and liver diseases. All company drugs are orally bioavailable with an excellent safety profile.

Can-Fite intellectual property includes more than 100 individual cases, protecting the composition of matter, clinical applications and way of synthesis matters. The company has 43 publications in peer reviewed scientific journals.

Pipeline:

Can-Fite has license agreements with Seikagaku Corporation (Japan) and Kwang Dong (Korea).

MANAGEMENT

Pnina Fishman, Ph.D., Chief Executive OfficerMotti Farbstein, COO & Financial DirectorBarak Singer, VP Business Development

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

CELL MED Research GmbH www.cellmed.at

CONTACTSDr Wolfgang Huber Chief Executive Officer

ADDRESSMagnesitstraße 1 3502 Krems Lerchenfeld Austria

TELEPHONE+43 2732 70512-0

FAX+43 2732 70512-50


YEAR FOUNDED2006

FINANCIAL SUMMARY

Company already raised EUR 9.3 million for the project

EUR 7 million investment required to fund the next milestones in the clinical development.

COMPANY PROFILE

CELL MED Research GmbH is a CMO (Contract Manufactoring Organisation) running a GMP (Good Manufacturing Practice) approved laboratory and production site in Krems/Donau, near to the Austrian capital, Vienna.

MANAGEMENT

Dr Wolfgang Huber, Chief Executive Officer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

CerMed International www.cermedcorp.com

CONTACTSSteve Roon

Caroline Bergmann MC Services AG

ADDRESSCerMed International 2511 Garden Road, Suite B100 Monterey CA 93940 USA

TELEPHONE+1-831-920-2275

Caroline Bergmann MC Services AG +49-89-210228-20

FAX+1-831-920-2276


[email protected]

caroline.bergmann @mc-services.eu

YEAR FOUNDED2008

COMPANY PROFILE

CerMed International (FSE:CRX) is a medical device company that serves global billion dollar markets supporting women’s health needs in cervical cancer detection, HIV protection and contraception. The Company will launch CerMap, the world’s first combined cervical specimen collection and mapping system, in Q4 2011 under a $20m contract for cervical screening systems with Audit Diagnostics. These will be distributed initially in China then other key markets across Asia and Eastern Europe. Additionally, CerMark is being developed as the world’s only point-of-care cervical cancer screening device. This break through technology is a major advance over current screening processes, which significantly improves the effectiveness, affordability and usability for patients and clinicians. CerMark will facilitate the early detection and treatment of women globally, especially in developing countries. In September 2011, CerCap, a drug eluting cervical cap barrier contraceptive, will begin clinical trials supported by the University of California and the University of Zimbabwe. CerCap enables women control in preventing pregnancy and reducing the risk of HIV infection. CerMed’s management team provides extensive expertise in life sciences and in building and managing successful companies.

MANAGEMENT

Peter Gombrich, CEOWendell Jones, II, CFOJimmy LeeKen HolbrookRobryt ReganMary Ruberry

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Cevec Pharmaceuticals GmbH www.cevec.com

CONTACTDr Rainer Lichtenberger Chief Executive Officer

ADDRESSGottfried-Hagen-Str. 62 51105 Koeln

TELEPHONE+49 221 460208 00

FAX+49 221 460208 01


YEAR FOUNDED2001

FINANCIAL SUMMARY

Since late 2008 CEVEC successfully markets its cell based technology for protein and antibody production. The company has attracted 10 Mio. EUR venture capital in several venture rounds up to now. Most recently an additional venture round over 6 Mio EUR could be closed with their existing investors. Lead investors include Creathor Venture and NRW.Bank.

COMPANY PROFILE

The CAP vaccine business case:

CEVEC commercializes of an innovative platform technology for the production of vaccines and biopharmaceuticals in human cell lines.

CEVECs CAP cells hold high promise for as best-in-class production system for Influenza vaccines and other virusal vaccines, as shown by a recent case study. Compared to leading other cellular production systems (like MDCK) CAP demonstrated outstanding results in view of virus yield, extreme short production cycles and minimal media consumption. CEVECs CAP system is suspension based and serum free offering the best starting point for new vaccine production approaches with excellent upscaling possibilites. Being the only remaining independent supplier for human production cell lines, the company sets out to repeat the growth story of Crucell B.V., recently acquired by Johnson & Johnson for 2.4 Bn US$.

Feasibility studies demonstrated CAP being a versatile virus production platform with the broadest possible array of human viruses potentially replicating on them. Commercially significant targets include hCMV, RSV, Influenza, Polio, Measles, AAV, Adenoviruses, Lentiviruses and others. 3 lead projects have been identified and planned, including the first human platform for hCMV, together with its partner Vaccine Project Manager, Hannover, Germany.

CEVEC heads out in 2nd half of 2011 to raise another 7-10 Mio. EUR venture round. Aim of this investment will be to push the vaccine lead projects, hCMV influenza and RSV within 3 years to clinical phase I results and manage a broad roll-out of its vaccine production technology in order to maximize its company exit value by 2015. New venture investors are now invited to participate in an exciting low-risk and high return growth story.

For further information, please visit: www.cevec.com

MANAGEMENT

Dr Rainer Lichtenberger, CEOWolfgang Kintzel, Managing Director/CCODr Gudrun Schiedner, CSODr Nicole Faust, VP Development & ServicesGary Boch, VP BD North AmericaDr Hartmut Tintrup, Dir. BD Europe & Asia

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

ChromaCon AG www.chromacon.ch

CONTACTGuido Stroehlein, PhD MBA CEO

Michael Bavand, PhD CBO

ADDRESSTechnoparkstr. 1 8005 Zuerich Switzerland

TELEPHONE+41-44-445 20 10


YEAR FOUNDED2007

FINANCIAL SUMMARY

ChromaCon has been profitable since inception.

COMPANY PROFILE

ChromaCon AG is a biopharmaceutical company that develops and markets enabling bioprocess solutions for the biopharmaceutical industry. It also collaborates with partners in the development of biopharmaceutical projects.

Its patent-protected, best-in-class technology platform (Contichrom™) enables the development of previously not accessible novel biological medicines and life cycle products with improved characteristics such as bispecifics antibodies, glycosylation variants, PEGylated proteins. Besides the enabling features, the Contichrom™ platform allows to reduce CAPEX and COGs by up to 50% for the production of biologics.

ChromaCon’s business model is based on equipment sales through distribution partners and on commanding license fees on production equipment use.

MANAGEMENT

Guido Stroehlein, CEOMichael Bavand, CBOThomas Müller-Späth, CSOLars Aumann, CTO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Covagen AG www.covagen.com

CONTACTSDr Julian Bertschinger Chief Executive Officer

Dr Dragan Grabulovski Chief Scientific Officer

ADDRESSCovagen AG Wagistrasse 25 Schlieren, 8952 Switzerland

TELEPHONE+41 44 732 46 60

FAX+41 44 732 46 64


YEAR FOUNDED2007

FINANCIAL SUMMARY

Investors: Novartis Venture Fund, Edmond de Rothschild Investment Partners, Ventech, Seroba Kernel Life Sciences, MP Healthcare Venture Management.

COMPANY PROFILE

Covagen (Zurich-Schlieren, Switzerland) is pioneering the commercialization of bispecific and multivalent next generation protein drugs (Fynomers) with novel, innovative mechanisms of action for the treatment of inflammatory diseases and cancer. Fynomers can be readily fused to antibodies which results in bispecific Fynomer-antibody fusions with increased potency and novel mechanisms of action. Furthermore, Fynomers can be assembled in a modular manner to create bispecific as well as multivalent Fynomers, which allow for treatment modalities that cannot to be exploited with antibodies.

TECHNOLOGY

Fynomers are novel, small binding proteins (7 kDa) derived from the fully human SH3 domain of the Fyn kinase. Fynomers can be engineered to bind to any target of interest with high affinity and specificity. Due to their favorable biophysical properties, Fynomers can be fused to the CH3 domain of full-size antibodies, which results in bispecific biopharmaceuticals with increased therapeutic efficacy and new mechanisms of action. Covagen is developing a bispecific TNF/IL-17A inhibitor.

MANAGEMENT

Board of DirectorsFrank Walsh, Executive ChairmanRay Hill Franz Hefti Anja König Gilles Nobécourt Karl Naegler Jon Hepple Julian Bertschinger

Scientific Advisory BoardUlrich Feige Thierry Hercend Christoph Heusser Christoph Lengauer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Curetis AG www.curetis.com

CONTACTOliver Schacht Chief Executive Officer

ADDRESSCuretis AG Max-Eyth-Str. 42 71088 Holzgerlingen Germany

TELEPHONE+49-7031-49195-12 +49-173-2147112

FAX+49-7031-49195-12


YEAR FOUNDED2007

FINANCIAL SUMMARY

Total of over 27 million € raised in seed round and Series A round; several German research grants (e.g. ZIM) to co-fund certain R&D projects.

Venture investors: aeris CAPITAL, LSP (Life Science Partners), BioMed Partners, CD-Venture, as well as KfW.

COMPANY PROFILE

Businessmodel:Product company – medical devices, molecular diagnostics

Expect a mix of direct product sales in home markets as well as distribution partnerships and R&D collaborations as well as commercialization alliances.

Technologies/Targets:Unyvero hardware platform and disposable cartridge-based molecular diagnostic system with integrated sample prep, DNA purification, multiplex PCR and array detection. First indication pathogen detection and antibiotic resistance detection in pneumonia.

Status:Start of pivotal clinical studies for EU and USA planned for 2011; Expected product launch in EU in 2012.

MANAGEMENT

Oliver Schacht, CEOAndreas Boos, Managing Director R&DJohannes Bacher, Managing Director OperationsAnne Thews, Director Marketing & Medical AffairsDr. Gerd Luedke, Director Bio-Assay DevelopmentAnne Burger, CFO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Cylene Pharmaceuticals, Inc. www.cylenepharma.com

CONTACTSWilliam G. Rice, Ph.D. President & Chief Executive Officer

Sean E. O’Brien, Ph.D.

Irene Alicea

ADDRESS5820 Nancy Ridge Drive Suite 200 San Diego CA, 92121 USA

TELEPHONE+1-858-875-5100

FAX+ 1-858-875-5101


YEAR FOUNDED2001

FINANCIAL SUMMARY

Series A $ 6.5 millionSeries B $26.5 millionSeries C $42.5 million

COMPANY PROFILE

Cylene Pharmaceuticals is a clinical-stage, private company designing and developing small molecule drugs against newly validated cancer targets. Cylene’s leadership in exploiting CK2-dependent pathways enables the creation of first-in-class agents (CX-4945 in Phase II and CX-8184 in preclinical development) that serve as the drug of choice in rational drug combinations for improved treatment outcomes against many cancer indications. The Company’s RNA Polymerase I (Pol l) Inhibitor program delivers first-in-class targeted agents (CX-5461 approaching Phase I) that act through the ideal non-genotoxic pathway for activating p53 to kill cancer cells. Cylene’s unique approach delivers innovative agents that enable pharmaceutical companies to expand their portfolios and extend the efficacy, lifecycle and reach of current cancer therapeutics.

Cylene’s approach to exploiting newly validated targets and key signaling pathways has created a pipeline of targeted cancer agents. These molecules, created in-house through Cylene’s unique mechanistic knowledge and chemistry expertise, are supported by an extensive intellectual property portfolio including 121 pending applications and 26 issued patents. The management team has the experience and talent to deliver these new agents as pharmaceutical drugs to patients and to the market. The company’s record of creativity, execution, frugality and pipeline creation have enabled Cylene to attract corporate and traditional venture capital investors alike. This solid foundation positions Cylene to deliver innovative drugs that will fulfill the unmet medical needs of cancer patients and their families.

MANAGEMENT

William G. Rice, Ph.D, President and Chief Executive OfficerDaniel D. Von Hoff, M.D., F.A.C.P., Co-founder and Vice President, Medical AffairsJohn K.C. Lim, Pharm.D., Senior VP, Clinical and Regulatory AffairsDavid M. Ryckman, Ph.D, Senior VP, Chemistry and Pharmaceutical Ops

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

DC Prime www.dcprime.com

CONTACTSProf Dr Ada M. Kruisbeek CEO & CSO

Aniek Büller Assistant to professor Kruisbeek

ADDRESSDe Boelelaan 1085 – F546 1081 HV Amsterdam The Netherlands

TELEPHONE+31 20 59 89 905

FAX+31 20 59 89 904


YEAR FOUNDED2005

COMPANY PROFILE

DCPrime is a clinical stage Dutch biotech company which has developed a unique platform technology, consisting of sustainable dendritic progenitor cells (named “DCOne™”) and a proprietary method to expand these and to create functional mature dendritic cells (DCs). Upon loading with cancer antigens, this generates standardized, off-the-shelf, dendritic cell-based therapeutic products, with great advantages over current DC vaccines.

DCPrime B.V. (DCPrime) is a spin-off company of the VU University Medical Center (VUmc) in Amsterdam, dedicated to developing a novel type of therapeutic vaccines. The company was founded in 2005 by Prof. Dr. Ada Kruisbeek and Prof. Dr. Rik Scheper.

It has become clear that DC-based vaccines can sometimes produce spectacular results in individual patients. Since DC-based vaccines are based on patient-derived DC, however, they pose significant logistical and standardization problems. DCPrime is creating a new type of DC-based vaccines that bypass the problems associated with patient-derived DC vaccines.

Unique Features

DCPrime is the first to test an allogeneic (non-patient-derived, standardized product) DC-based immunotherapy. This is based on its proprietary progenitor DC line, DCOne, and the processes to produce DC from this line. This should combine the expected superior allogeneic stimulation of the immune system, with the power of DC and off-the-shelf product characteristics. Such a standardized product is much more attractive from a production, operational and clinical perspective. Moreover, it concerns a technology platform that allows for different products to be made, each tailored to a specific kind of cancer. As such, DCPrime’s DCOne cell line is an immunotherapy platform applicable in a broad range of cancer types.

MANAGEMENT

Ada M. Kruisbeek, CEO & CSO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

CONTACTDr Titus Kretzschmar Chief Scientific Officer

ADDRESSDelenex Therapeutics AG Wagistrasse 27 CH-8952 Schlieren Switzerland

TELEPHONE+41 (0) 44-7305-180

FAX+41 (0) 44-7305-181


YEAR FOUNDED2009

FINANCIAL SUMMARY

Series A round financing completed in May 2011; 30.2 MCHF.

COMPANY PROFILE

Delenex Therapeutics AG is a clinical stage Swiss biotechnology company established in September 2009. It is focussing on the development of therapeutic antibody fragments.

Recently, 30.2 MCHF could be raised in a Series A round financing from already invested VCs and one new leading VC firm (Novo Ventures).

Delenex uses its proprietary, validated PENTRA® platform to develop best-in-class antibody fragments for therapy. Its PENTRA® technology rapidly produces drug-like fragments that exhibit highest affinities, solubilities and stabilities with a very low risk of immunogenicity. With initial focus on dermatological and CNS disorders local and topical applications of bacterially expressed antibody fragments are investigated to limit i. COGS as well as ii. side effects observable after systemic administration of antibodies.

Delenex has assembled an internationally recognized team with lots of years of experience gained in both the pharma and biotech world. It operates out of laboratories and offices in Schlieren/Zürich. For more details please review the company website www.delenex.com..

MANAGEMENT

Dr Eric de La Fortelle, Chief Executive OfficerDr Titus Kretzschmar, Chief Scientific OfficerMr Jakob Schlapbach, Chief Finance Officer Dr Thomas Jung, Chief Medical Officer

Delenex Therapeutics AG www.delenex.com

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

EnVivo Pharmaceuticals www.envivopharma.com

CONTACTSKees Been

Maiken Keson

ADDRESS480 Arsenal Street Watertown, MA 02472 USA

TELEPHONE+1 - 617-225 4210


YEAR FOUNDED2001

COMPANY PROFILE

EnVivo Pharmaceuticals, located in Watertown, Massachusetts, USA, is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with an emphasis on Alzheimer’s disease, cognition disorders and Schizophrenia. The company’s lead product EVP-6124 is an alpha-7 nicotinic acetylcholine receptor agonist being tested in Phase 2b clinical trials for cognition impairment in Alzheimer’s disease and Schizophrenia. The schizophrenia Phase 2b trial was recently completed in which EVP-6124 proved to have a positive effect on both the cognitive and negative symptoms as well as functional performance. Another clinical program is based on an epigenetics approach using EVP-0334 as a Histone Deacetylase inhibitor (HDACi) for cognition improvement and disease modification in several orphan indications. In addition, the company is testing EVP-0962, a Gamma Secretase Modulator in Phase I as a potential disease modifying agent in Alzheimer’s disease and has EVP-6308, a PDE10 inhibitor in IND-enabling studies for the positive symptoms of Schizophrenia.

The company currently employs 45 people and its main investor is Fidelity Biosciences.

MANAGEMENT

Kees Been, CEOStephen DiPalma, SVP Finance and CFODana Hilt, MD, SVP Clinical Development and CMOGerhard Koenig, PhD, SVP Research and CSOMaiken Keson, General CounselElaine Ouellette, VP HR

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Epigenomics AG www.epigenomics.com

CONTACTAntje Zeise

ADDRESSEpigenomics AG Kleine Präsidentenstr. 1 10178 Berlin Germany

TELEPHONE+49 30 24 34 5 0

FAX+49 30 24 34 5 555


YEAR FOUNDED1998

FINANCIAL SUMMARY

Epigenomics is publicly listed at the Frankfurt Stock Exchange, Prime Standard: (ECX, ISIN DE000A1K0516). For financial information please refer to the Investor Relations section of the Company’s website.

COMPANY PROFILE

Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international .

MANAGEMENT

Epigenomics is lead by a highly skilled and motivated management team of executives and senior vice presidents with track records in the industry in the U.S. and Europe.

The team is headed by CEO Geert Walther Nygaard (formerly Abbott, Dako, Beckmann Coulter) and CFO Dr. Thomas Taapken (formerly Biotie Therapies, Deutsche Venture, Burrill & Company).

Geert Walther Nygaard, CEODr Thomas Taapken, CFO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

f-star GmbH www.f-star.com

ADDRESSGranta Park Great Abington Cambridge CB21 6GS UK

TELEPHONE+44 (0)1223 896350

FAX+44 (0)1223 896351


YEAR FOUNDED2006

COMPANY PROFILE

f-star is a next generation antibody company developing improved therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology.

Modular Antibody Technology allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, small sized antibody fragments with full antibody functionality (Fcab™) or full length antibodies with additional functionality (mAb²) can be created.

Founded in 2006, the Company currently employs more than twenty highly qualified people at its research sites in Vienna, Austria and Cambridge, UK. In its Advisory Board, the Company is supported by pioneers in the research and development of monoclonal antibodies including Sir Ravinder Maini, Prof. Anthony Rees and Sir Gregory Winter.

f-star’s management team has many years of experience in the biotech and pharmaceutical industry, covering antibody engineering, pharmaceutical development, intellectual property, business development and finance.

f-star enjoys the strong financial support from a world-class group of life science investors including Aescap Venture, Atlas Venture, Novo A/S and TVM Capital.

MANAGEMENT

Dr Kevin FitzGerald, Chief Executive OfficerDr Kevin Moulder, Chief Scientific Officer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Faron Pharmaceuticals Ltd www.faronpharmaceuticals.com

CONTACTSDr Markku Jalkanen Chief Executive Officer

Dr Ilse Piippo VP Drug Development

Dr Mikael Maksimow Research Director

ADDRESSTykistökatu 6 B FIN-20520 Turku Finland

TELEPHONE+358-40-520-6124 +358-400-222-407 +358-50-330-8333

FAX+358-2-469-5153

EMAIL markku.jalkanen @faronpharmaceuticals.comilse.piippo @faronpharmaceuticals.commikael.maksimow @faronpharmaceuticals.com

YEAR FOUNDED2007

FINANCIAL SUMMARY

Private company. Operations funded from revenues, private and institutional equity and technology loans.

COMPANY PROFILE

Faron Pharmaceutical Ltd. is a privately owned clinical stage drug discovery and development company in Turku, Finland. Today Faron has three major drug development projects focusing on acute trauma, inflammatory diseases, and cancer spreading. Faron’s lead product FP-1201 has successfully passed a phase I/II study in the UK to treat vascular leakage in ALI/ARDS patients. Faron is currently expanding the FP-1201 program to a pan-European pivotal phase III study that company hopes to get started in H2-2012. The primary efficacy endpoint in this study will be all cause mortality at day 28, which decreased below 10 % in the above mentioned phase II study from commonly observed 35-40 %.

MANAGEMENT

Very seasoned life science managers (see contacts above) with significant experience from early drug development coordinate operations. Large network of world-class pharma experts support company operations. Faron Board consists of two lawyers and three pharma experts.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Galantos Pharma GmbH www.galantos.com

CONTACTSSandra Gerdemann

Jutta Blesius

ADDRESSGalantos Pharma GmbH Freiligrathstraße 12 55131 Mainz

TELEPHONE+49 6131 1440-311

FAX+49 6131 1440-329


YEAR FOUNDED2005

FINANCIAL SUMMARY

€ 9 million in three investment rounds and grants

COMPANY PROFILE

Introduction

Galantos Pharma GmbH is a biopharmaceutical company developing innovative drugs for the treatment of neurodegenerative diseases. At present, its focus is on the improvement of marketed drugs and natural substances for the treatment of Alzheimer’s Disease (AD).

The company was founded in 2005 by Profs. Alfred Maelicke (Mainz) and Ulrich Jordis (Vienna) as a spin-off of Maelicke’s Laboratory of Molecular Neurobiology at the University of Mainz Medical School, Germany. Memogain, its most advanced product, is scheduled to move into clinical trials in 2011 and has shown potent symptomatic improvement and plaque reduction in animal models.

Long-standing expertise in Alzheimer’s disease

The founders of Galantos Pharma GmbH have a long-standing experience in the neurochemistery of AD and have been proponents of galantamine as a drug to reduce cognitive impairment in AD. Maelicke’s laboratory demonstrated, among others, that AD is accompanied by a severe loss of nicotinic acetylcholine receptors (nAChR). It later identified a novel class of nAChR ligands capable of enhancing the activity of remaining nAChRs, the so-called allosteric potentiating ligands (APLs), which provide a very safe mechanism for symptomatic improvement and disease modification.

Pipeline

The lead product of Galantos Pharma is Memogain, a very safe and potent derivative of galantamine. Currently galantamine is arguably the best marketed treatment for AD and lost patent protection in 2009. Galantos’ Memogain is an inactive prodrug effectively delivering active galantamine into the brain. It offers improved effectiveness at much reduced toxicity. Preclinical investigations have demonstrated improved potency for symptomatic improvements and reduced Alzheimer-plaque formation in a mouse model. GLP toxicity has demonstrated very low toxicity. Clinical phase I will start in the second quarter of this year.

Clinical development is largely supported by the fact that Memogain is completely metabolized to the pharmacologically active compound which approved since 2000.

In addition, the Galantos is exploring novel neuroprotective compounds (APLs) targeting nicotinic acetylcholine receptors in general (nAChRs) and a subtype-specific enhancers of nicotinic acetylcholine receptors. APLs provide a very safe mechanism to enhance the sensitivity of receptors that are progressively lost during AD. Results in animal models indicate that enhancing the sensitivity of nAChRs has considerable therapeutic potential in AD and other CNS-related diseases.

Commercialization Strategy

Galantos’ strategy is to achieve a fast and rewarding return of investment for its first project and to co-fund development of the research funded earlier pipeline.

The Company will bring Memogain into clinical phase I this year and license the drug to a pharma partner for later clinical development and marketing. For the earlier stage pipeline, Galantos aims to form strategic alliances with pharma partners to reduce development costs and attrition rate of Alzheimer’s medication candidates, creating a revenue stream.

continued...

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Galantos Pharma GmbH www.galantos.com

CONTACTSSandra Gerdemann

Jutta Blesius

ADDRESSGalantos Pharma GmbH Freiligrathstraße 12 55131 Mainz

TELEPHONE+49 6131 1440-311

FAX+49 6131 1440-329


YEAR FOUNDED2005

...continued

MANAGEMENT

Prof Dr Alfred Maelicke, CSOKey founder and Head of R&D of the company. He was Professor of Biochemistry and Department Head at the Medical Faculty of the University of Mainz, where he focused on molecular and cellular aspects of development and degeneration in the human brain, and on drug development for Alzheimer’s disease. In 2005, he founded Galantos Genetics and Galantos Pharma and since then headed the R&D program of Galantos Pharma.

Dr Andreas Köpke, CBOResponsible for business development, and operations of the company. Dr Köpke has 10 years of international academic research and 15 years of management experience in the pharmaceutical and biotech industry: as Head of Business Development Pharma (Devgen), CEO (WITA Proteomics) and Associate Director of Collaboration & Technology Transfer Janssen Pharmaceutica (Johnson & Johnson) he has created effective departments, closed more than 20 important deals, initiated and led merger discussions, and took part in an IPO and a company sale. While working at Janssen, he became acquainted with galantamine and Prof Maelicke.

Dr med. Karl Krista, CFO, Responsible for financial planning, financing and commercialization. He has 19 years of international industrial experience including: former CEO of CellControl and Senior Engagement Manager at McKinsey.

Dr Titus Kaletta, Head of R&D Has more than 10 years of relevant industry experience, incl. Department Head at Devgen.

Prof Dr Ulrich Jordis, co-founder of the company and Head of the Laboratory of Applied Chemical Synthesis at the Technical University of Vienna.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

GlycoVaxyn AG www.glycovaxyn.com

CONTACTAngela Arena Executive Assistant

ADDRESSGlycoVaxyn Grabenstrasse 3 8952 Schlieren Switzerland

TELEPHONE+41 44 733 85 85

FAX+41 44 733 85 74


YEAR FOUNDED2004

FINANCIAL SUMMARY

So far, the company has raised CHF 37.5 million in series A and B from blue-chip European VCs including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners.

COMPANY PROFILE

GlycoVaxyn is a clinical-stage, private bio-pharmaceutical company designing and developing vaccines to address unmet medical needs in prevention of bacterial diseases worldwide. GlycoVaxyn was founded in 2004 as a spin-out of the Swiss Federal Institute of Technology of Zurich (ETHZ) to develop and commercialise applications of its proprietary bioconjugation technology. GlycoVaxyn is based in Switzerland, and currently employs 38 people.

MANAGEMENT

Philippe Dro, CEO Michael Wacker, CSO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Heptares Therapeutics Ltd www.heptares.com

CONTACTMalcolm Weir Chief Executive Officer

ADDRESSHeptares Therapeutics Ltd BioPark Broadwater Road Welwyn Garden City Hertfordshire AL7 3AX

TELEPHONE+44 1707 358 629 +44 7968 947 268


YEAR FOUNDED2007

FINANCIAL SUMMARY

$40M venture finance to date from Clarus Ventures, MVM Life Science Partners, Novartis Option Fund and Takeda Ventures.

COMPANY PROFILE

Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs). The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases.

GPCRs represent the single most important family of drug targets in the human body, yet, due to their inherent instability when removed from cell membranes, little or no structural information about these valuable targets has been available to drive structure-based drug discovery (SBDD) programmes. Heptares’ StaR® (Stabilised Receptor) technology enables the first-ever thermo-stabilisation of GPCRs. This breakthrough allows Heptares scientists to resolve GPCR structures and deploy structure-based drug discovery techniques to identify potent and selective drug candidates to previously undruggable targets.

• Four-year collaboration with AstraZeneca (2011) focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.

• Exclusive option agreement with Shire (2011) for novel small molecule adensoine A2A antagonist with best-in-class potential for the treatment of CNS diseases. To our knowledge, this is the first-ever GPCR candidate to arise solely from SBDD.

• Approximately $100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.

• $200 million alliance with the Novartis Option Fund (2009) focused on single GPCR target of strategic interest to Novartis. Novartis and Heptares jointly announced the successful first-ever stabilisation of this previously intractable GPCR using the Heptares technology.

MANAGEMENT

Dr Malcolm Weir, Co-Founder and Chief Executive Officer Dr Fiona Marshall, Co-Founder and Chief Scientific Officer `Dr Barry Kenny, Chief Business Officer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

immatics biotechnologies GmbH www.immatics.com

CONTACTMark Bleckmann Director & Head of Finance

ADDRESSimmatics biotechnologies GmbH Paul-Ehrlich-Straße 15 72076 Tuebingen Germany

TELEPHONE+49 7071 5397 100

FAX+49 7071 5397 900


YEAR FOUNDED2000

FINANCIAL SUMMARY

Three financing rounds concluded. A total of € 108m raised.

COMPANY PROFILE

immatics is developing cancer vaccines that help to activate the self defense mechanisms of the human body.

Our goal is to support patients and physicians with new options in the fight against various cancers.

Our means are synthetic peptides that specifically activate specialized white blood cells of the patient’s immune system against cancer cells.

MANAGEMENT

Paul Higham, Chief Executive OfficerDr Harpreet Singh, Chief Scientific OfficerDr Carsten Reinhardt, Chief Medical Officer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Immune Targeting Systems www.its-innovation.com

CONTACTCarlton Brown Chief Executive Officer

ADDRESSImmune Targeting Systems (ITS) Ltd c/o London Bioscience Innovation Centre 2 Royal College Street London NW1 0NH United Kingdom

TELEPHONE+44 20 7691 4908

[email protected] [email protected]

YEAR FOUNDED2003

FINANCIAL SUMMARY

The company has raised nearly £14.5m of funding via a seed (2004) and series-A (2007 / 2010) from Blue chip investors including the Novartis Venture Fund, HealthCap, Truffle Capital, the London Technology and Esperante Ventures. This funding also included £0.5m grant funding from the London Development Agency.

COMPANY PROFILE

Immune Targeting Systems (ITS) is London based Biotech Company developing vaccines for mutating viruses underpinned by its DepoVaccine™ and Densigen™ technology platforms. ITS’ lead program, a synthetic universal influenza vaccine (Flunisyn™) targeting all potential seasonal and pandemic flu strains, is currently completing phase-I clinical testing. Flunisyn™ clinical data highlights it is safe and well tolerated and immunology data confirms its best in T-cell vaccine class potential and validates this unique approach to vaccine design. A phase-II efficacy study will initiate in 2011.

DepoVaccines deliver Densigens™ to the immune system promoting a short-term vaccine injection site depot to promote potent, durable and recallable antiviral T-cell immunity. DepoVaccine™ delivered Densigens™ contain multiple different rationally selected long peptide antigen sequences (35aa) which are conjugated to a fluorocarbon molecule. This yields a thermostable freeze dried nanoparticle formulation when formulated. Vaccine antigen selection focuses on selecting highly conserved antigens (cross strain/genotype) to ensure a T-cell response which is capable of providing broad population coverage and a vaccine responder frequency targeting >90% without restrictive HLA sub-type selection, a multi-peptide breadth of response exceeding current best-in-class and a potent-durable magnitude of response. Synthetic peptide based vaccines are well suited for chronic disease treatment because they boost T-cell responses upon revaccination, without requiring heterologous prime-boost strategies using a second vaccine technology (contrast DNA & viral vector technologies).

DepoVaccines™ represent an ideal immunotherapy platform for HBV, HCV, cancers, in addition to Influenza-A. ITS welcomes partnering discussions. Contact: [email protected]

MANAGEMENT

Carlton Brown, Chief Executive OfficerCampbell Bunce, Ph.D, R&D DirectorTim Cowper, Finance DirectorBertrand Georges, Ph.D, Chief Technical OfficerJill Makin, Ph.D, Head of Vaccine Manufacture

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Ingentyx www.ingentyx.com

CONTACTPer Horn, Ph.D Chief Executive Officer

ADDRESSBaltorpvej 154 2750 Ballerup Denmark

TELEPHONE+45 2081 5802 (mobile)


YEAR FOUNDEDPrimo 2012 (expected)

FINANCIAL SUMMARY

Ingentyx is aiming to raise milestone-driven tranche-released equity finance totaling approx. €5 million to launch and run the company for 3 years; enabling the development of new biological drugs for the treatment of immunological diseases. The principal objective of the financing is to fund our discovery, evaluation and development activities, including in vivo studies with established animal models and testing of prime candidates with patient materials. Ingentyx will furthermore invest in maintaining and expanding the intellectual property rights protecting mainly its biological products but also technologies.

COMPANY PROFILE

Ingentyx is based on the combined expertise of Intomics, NsGene and Celentyx. Intomics and Celentyx are currently using their state-of-the-art facilities and technologies as CROs for major pharmaceutical companies and NsGene has entered a multimillion dollar contract with a major biotechnology company for one of its therapeutic proteins.

By combining the activities of these 3 companies into Ingentyx, we will be able to discover, evaluate and develop new therapeutic candidates for the treatment of immune related diseases.

In 2012 we expect to establish 5 new potentially therapeutic candidates for comprehensive immuno-profiling.

In 2013 we expect to file at least one patent application for a novel therapeutic protein and we expect to have out-licensed at least 2 therapeutic proteins by the end of 2014, whereafter a strategic alliance or an M&A are very realistic options.

Ingentyx has a clear exit strategy in the form of an M&A.

MANAGEMENT

Per Horn, Ph.D, Chief Executive Officer

Dr. Horn (Presently Head of Novel Biologics, NsGene) did his undergraduate studies at University of Southern Denmark (1989-1993) and spent the following 3 years at Tokyo Institute of Technology (1993-1996). The work performed in Japan earned him a Master of Biotechnology degree. Dr. Horn then spent a year at Cambridge University, UK at the Brain Repair Centre which was concluded with a Master of Philosophy degree in Neuroscience (1996-1997). From 1997 to 2006, Dr. Horn was associated with Aarhus University where he earned a PhD degree in Medicine. In 2007, Dr. Horn had a short stay at Statens Serum Institute before being recruited to NsGene to head the factor discovery program which eventually became the novel biologics program. Dr. Horn has been responsible for developing these programs at NsGene in close collaboration with academic groups, including Søren Brunak and his group at the Danish Technical University, Denmark and he has more than 10 years experience in bridging the gap between bioinformatics and experimental biology. Dr. Horn has authored more than a dozen scientific publications, book chapters and patent applications.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

InteRNA Technologies B.V. www.interna-technologies.com

CONTACTRoel Q.J. Schaapveld Chief Executive Officer

ADDRESSHugo R. Kruyt building Padualaan 8 3584CH Utrecht Netherlands

TELEPHONE+31 30 253 2386

FAX+31 30 253 9176

EMAIL schaapveld @interna-technologies.com

YEAR FOUNDED2006

FINANCIAL SUMMARY

Seed.

COMPANY PROFILE

InteRNA Technologies is a Dutch early stage drug discovery and development company with the mission to develop miRNA-based pathway targeted therapeutics for cancer. With its proprietary lentiviral-based miRNA expression library (the largest currently available) InteRNA takes a unique holistic R&D approach and focuses on the demonstration of the function of its miRNAs in a number of cancer indications through functional screens. This approach results in the rapid identification of multiple novel drug candidates, which provide a steady basis for further validation and clinical drug development. InteRNA has exclusive IP rights to a vast collection of novel miRNA sequences (not in public domain/miRbase), to technologies for identification and detection of miRNAs and to diagnostic and therapeutic uses of certain miRNAs in disease.

MANAGEMENT

Roel Q.J. Schaapveld, PhD, MBA, CEOGrégoire Prevost, PhD, CDO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Invetech www.invetech.ch

CONTACTSAndreas Koch, PhD

Peter Aigner, PhD

ADDRESSIndustriestrasse 25 8604 Volketswil (Zurich) Switzerland

TELEPHONE+41 78 881 0376

FAX+41 44 536 0412


YEAR FOUNDED1988

COMPANY PROFILE

Invetech is a global innovator in instrument and new product development, custom automation and contract manufacturing with extensive experience in diagnostics, cell therapy, medical devices and drug discovery. Invetech has a staff of more than 200, with specialist expertise in innovative design, engineering and manufacturing. We are ISO 9001:2008 certified and our quality system and development processes are compliant with FDA QSR (Quality System Regulation) for biomedical products and with GAMP (Good Automated Manufacturing Process) for custom automation. Our manufacturing facilities are ISO13485:2003 certified, supported by regular reviews and audits with world leading biomedical clients such as Abbott, bioMérieux and Bio-Rad.

MANAGEMENT

Invetech is part of Leica Microsystems which belongs to the Danaher group of companies.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

ISA Pharmaceuticals BV www.isa-pharma.com

CONTACTMaaike Vogelezang Management Assistant

ADDRESSISA Pharmaceuticals BV Niels Bohrweg 11-13 2333 CA Leiden The Netherlands

TELEPHONE+31 (0) 71 3322310

FAX+31 (0) 71 3322311


YEAR FOUNDED2004

FINANCIAL SUMMARY

Fundraising series B.

COMPANY PROFILE

ISA Pharmaceuticals is a clinical stage company developing novel therapeutic products for cancer and infectious diseases. ISA exploits its proprietary SLP® technology to achieve therapeutic effects in a number of indications. The most advanced product under development is a therapeutic SLP-HPV® vaccine for the treatment of patients suffering from Human Papilloma Virus type 16 (HPV16) associated (pre-) malignant disorders.

MANAGEMENT

Gerard Platenburg, CEOCornelis Melief, CSOJohan Frieling, CMO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

LSK BioPharma www.lskbiopharma.com

CONTACTSAlex Kim Executive Vice President

ADDRESS8 East Broadway Suite 611 Salt Lake City Utah 84111 USA

TELEPHONE+1(801) 303 7440

FAX+1(801) 303 7455


YEAR FOUNDED1995

FINANCIAL SUMMARY

Private Corporation.

COMPANY PROFILE

LSK BioPartners, Inc. (dba LSK BioPharma, “LSKB”) is a US-based drug development company managed by industry experts who have a successful track record of developing next-generation cancer drugs. The Company has the exclusive worldwide rights (excluding China) to the new chemical entity YN968D1 (apatinib mesylate), originally synthesized and developed by Advenchen Laboratories in California. This drug has completed Phase 1/2/3 clinical trials in China and is being studied in patients with Advanced Gastric Cancer, Metastatic Breast Cancer and Advanced Hepatocellular Carcinoma. YN968D1, which has a global market potential of almost $2.5 Billion, is expected to receive market approval in China by late 2011.

LSKB completed a Pre-IND meeting with the US FDA in July of 2011 and intends to file an IND in the third quarter of 2011. The Company has secured funding for non-clinical and clinical trials through a non-dilutive global co-development deal with Bukwang Pharma, a major Asian pharma company. LSKB management forecasts a cash needs of about $1.4 million to support internal operations and milestone payments through the end of 2013 when YN968D1 is expected to be in Phase 2 clinical trials. The Company intends to raise this amount in 2 tranches over the next two years as milestones are met.

The Company intends to sell or outlicense YN968D1 to a major pharmaceutical company for pivotal trials and marketing during the US Phase II clinical trials. With the successful development of YN968D1 through early clinical trials in the US, LSKB intends to continue leveraging its expertise in the niche development area of preclinical to early clinical trials by in-licensing new opportunities.

MANAGEMENT

Sung Chul Kim, Ph.D., President & CEODr. Kim founded LSKB as a business development and regulatory consulting firm. He has over 20 years experience in the pharmaceutical industry covering areas such as product development, preclinical studies, clinical trials, cGMP manufacturing, Korean and US RA. He was VP of Samyang Research Corporation, a US-based DDS company. He also held principal researcher positions in R&D at Samyang Corporation where he was instrumental in developing two successful oncology products. His academic experience includes a Ph.D. in Pharmaceutics, Sungkyunkwan University, an M.S in Pharmaceutics and a B.S. in Pharmacy from Sungkyunkwan University.

Alex S. Kim, M.A., Executive Vice PresidentMr. Kim joined LSKB in May of 2007. In December of 2007, he was elected to the Board of Directors. Mr. Kim has 20 years experience in the pharmaceutical industry at MacroMed, Inc. (now BTG, Plc); Expression Genetics, Inc.; VivoRx, Inc. (now Abraxis Pharmaceuticals); Theratech (now Watson Pharmaceuticals). Mr. Kim’s experience at these companies includes executive management, business development, product and technology licensing, strategic planning and M&A activity. He received his Masters Degree in International Business from Sophia (Sang Ji) University in Tokyo, Japan and Bachelors Degree from the University of Utah.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

MDxHealth SA www.mdxhealth.com

CONTACTSDr Jan Groen Chief Executive Officer

Mr Philip Devine Chief Finance Officer

ADDRESSMDxHealth SA Avenue de l’Hôpital, 11 Tour Giga + 3 LIEGE, 4000 BELGIUM

TELEPHONE+32 4 364 20 70

FAX+32 4 364 20 84


YEAR FOUNDED2003

FINANCIAL SUMMARY

December 2010 in ‘000 EUR

Commercial revenues 1,968Operating costs 10,532Of which are R&D related 6,812EBIT - 8,366Cash burn 7,439Cash in hand 10,593Financial debt 0

Q2 – Company raised 8,2 million EUR – Cash on hand : 16 million EUR – 1,1 million $ new grant for Bladder cancer

Outlook – Clinical validation/data of prostate products – New partnering deals with big pharma – Establish its own US-based CLIA certified laboratory – Start recruiting a US based sale force.

COMPANY PROFILE

MDxHealth is a leading molecular diagnostics company that develops and commercializes molecular diagnostic products for personalized medicine. The company’s numerous cancer tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck KGaA, Qiagen, Pfizer and other industry leaders.

MANAGEMENT

Senior ManagementDr Jan Groen, CEOMr Philip Devine, CFOProf. Wim Van Criekinge, VP Sciences & TechnologyMr Joseph Sollee, VP Legal AffairsDr Melissa Thompson, VP Reg. Affairs & QualityDr James Clark, VP R & DMrs Miriam Reyes, Sr Dir. Lab. OperationsMr Christopher Thibodeau,VP Com. Operations

Board of Directors/AffiliationMr Raphaël Wisniewski, Edmond de Rothschild Investment PartnersDr Karin Dorrepaal, IndependentMrs Hilde Windels, IndependentMr Mark Myslinski, IndependentMr Edward Erickson, IndependentMr Rudi Mariën, Gengest BVBADr Jan Groen, MDxHealth

Scientific Advisory BoardProf Jonathan Epstein Prof James Herman Prof Gerrit Meijer Dr Eric Wallen

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Micropharma Limited www.micropharma.net

CONTACTSRyan Jones Chief Executive Officer

Dr. Chris Wahl Director of Business Development

ADDRESS141 Ave. President Kennedy 5th Floor UQAM – Biological Sciences Building Unit 5569 Montreal Quebec Canada H2X 3Y7

TELEPHONE514 977 3000

Ryan Jones 514 987 4151

Dr Chris Wahl 514 987 4151 x3

FAX514 987-4616


YEAR FOUNDED2003

FINANCIAL SUMMARY

Stage: Premarket

Revenue: $1,000

Monthly Burn: $30

Current Assets: $4,100

Previous Capital: $12,200

COMPANY PROFILE

Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria with interesting phenotypic traits that target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to over express desirable traits of the organism. The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world’s first disease-specific, biomarker linked, and therapeutic bacteria product. Micropharma is using ProSelect to develop a pipeline of candidates to out-license or partner as over-the-counter or biotherapeutic products. Micropharma has one market-ready product LrC (Cardioviva™) for hypercholesterolemia and two products underdevelopment including, Lr54 for type two diabetes, and La101 for chronic liver disease (CLD) and minimal hepatic encephalopathy (MHE). Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in a proof-of-concept study. Cardioviva™ works by deconjugating bile, reducing dietary absorption of cholesterol, and increasing catabolism and excretion of cholesterol. A second proof-of-concept study using a BSH-optimized Cardioviva™ formulation is ongoing. Our two unpartnered preclinical products include: Lr54 was selected and optimized to produce a unique set of proteins and is proving to be highly effective for treatment of type two diabetes working through a combination of anti-inflammation, increased glucose metabolism, and decreased glucose uptake. La101, decreases urease producing bacteria in the gut, gut porosity, and has a very unique bioavailable polyphenolic acid fingerprint in blood leading to increased ammonia detoxification, reduced inflammation, decreasing endotoxins, and reducing reactive oxygen and nitrogen species in blood.

MANAGEMENT

Ryan Jones, BEng, CEOTen year track record of success in raising capital, business development, and management of life science companies

Dr. Chris Wahl, MD, MBA, Dir. Bus. DevelopmentWorked at McKinsey and Co. in the Pharmaceutical and Medical Products Practice as a consultant to Pharmaceutical, Medical Device and Biotechnology companies, worked at Merck Frosst Canada in the Patient Health Management Group, expert in strategy, regulatory, reimbursement, and commercialization.

Dr. Mitchell Jones, MD and PhD (Biomedical Engineering), CSO Co-founder of Micropharma, inventor of all relevant Micropharma technology including Cardioviva™ and ProSelect, expert in product discovery and development, expert in clinical medicine.

Dr. Satya Prakash, PhD (Biomedical Engineering), Director and Co-founderCo-founder of Micropharma, professor of biomedical engineering at McGill University, expert in bacteria as therapeutics and delivery technologies, 150 peer-reviewed articles, listed as an inventor in 27 patents, and author of three books on the topic.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Molecular Partners AG www.molecularpartners.com

CONTACTSDr Christian Zahnd Chief Executive Officer

Andreas Emmenegger Chief Financial Officer

ADDRESSMolecular Partners AG Wagistrasse 14 8952 Zürich-Schlieren Switzerland

TELEPHONE+41 44 755 7700

FAX+41 44 755 7707


YEAR FOUNDED2004

FINANCIAL SUMMARY

Series A (July 2007): CHF18.5m

Series B (Dec 2009): CHF46m

Investors: Essex Woodlands Health Ventures • Index Ventures • Johnson & Johnson Development Corporation • BB Biotech Ventures • Endeavour Vision

COMPANY PROFILE

Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. DARPins are as target specific and potent as monoclonal antibodies. Yet, being small proteins, they overcome the known limitations of conventional protein-based therapeutic approaches. We address real medical needs and develop cutting-edge medicine based on innovative DARPin products.

The DARPin platform has rapidly generated a differentiated pipeline of drug candidates. The most advanced DARPin is MP0112, a long acting VEGF antagonist, which has completed two separate Phase I/IIa clinical trials in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), the most common causes for vision loss.

In May 2011, MP0112 was out-licensed to Allergan Inc. for $45 million up-front payment, $375 million development, regulatory and sales milestones and tiered double-digit royalties on any future sales of MP0112.

Further compounds are in preclinical development and late stage research in oncology, inflammation and ophthalmology.

In addition to our fully owned drug candidates, several DARPins are being developed in partnership with major biopharmaceutical companies.

Molecular Partners is backed by a very strong international syndicate of institutional and corporate investors.

MANAGEMENT

Dr Christian Zahnd, CEODr Michael Stumpp, CSODr Patrick Amstutz, CBO Andreas Emmenegger, CFO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

MolMed S.p.A. www.molmed.com

CONTACTHolger Neecke Director Business Development and Investor Relations

ADDRESSMolMed S.p.A. via Olgettina 58 Milan 20132 Italy

TELEPHONE+39 02 21277 1

FAX+39 02 21277 325


YEAR FOUNDED1996

FINANCIAL SUMMARY

Public company, listed on the Milan Stock Exchange since March 5, 2008, at the Standard segment (class I) of the MTA managed by Borsa Italiana.

Share capital increase completed in August 2010, with gross proceeds of € 57.8M.

Market Cap (07/07/11): € 122.4M.

Shareholders (21/06/2011): FININVEST SpA 23.941% SCIENCE PARK RAF SpA 10.488% H-Equity Srl 4.062% H-Invest SpA 4.062% Airain Lda 7.107% Delfin Sàrl 4.297% Lombard Int. Assurance SA 2.493% Others (free float) 43.549%

COMPANY PROFILE

MolMed S.p.A. is a biotechnology company established focused on research, development and clinical validation of novel anticancer therapies.

MolMed’s pipeline includes two investigational therapeutics, both in Phase III :

• TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III for high-risk leukaemia;

• NGR-hTNF, a novel vascular targeting agent, in Phase III for malignant pleural mesothelioma and in Phase II in six other types of solid tumours: colorectal, small-cell lung, non-small-cell lung, liver and ovarian cancer.

MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy.

MolMed shares (Milan:MLM) are listed on the Milan Stock Exchange (Standard segment, class I) of the MTA managed by Borsa Italiana.

MANAGEMENT

Senior Management:Claudio Bordignon, CEOMarina Del Bue, General Manager Business & AdministrationGermano Carganico, General Manager R&D and Operations

Board of Directors:Claudio Bordignon, ChairmanLuigi BerlusconiSilvio Bianchi Martini, Lead independent directorRenato BottiMaurizio CarfagnaPaolo M. CastelliRiccardo Cortese, IndependentMarina Del Bue, Executive DirectorAlessandro De Nicola, IndependentMassimiliano FrankSabina GrossiAlfredo MessinaMaurizio Tassi

Scientific Advisory Board:Claudio Bordignon, ChairmanCarl-Henrik HeldinRobet KerbelAlberto SobreroDidier Trono

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Mucosis B.V. www.mucosis.com

CONTACTDr Govert Schouten Chief Executive Officer

ADDRESSMucosis B.V. L.J. Zielstraweg 1 9713 GX, Groningen The Netherlands

TELEPHONE+31 (50) 8200050 (T) +31 (6) 55320948 (M)

FAX+31 (50) 8200051


YEAR FOUNDED2006

FINANCIAL SUMMARY

Series A: €3,000,000 (2007)

Inn.Credit: €3,000,000 (2010)

Current Investors: Biogeneration Ventures • MedSciences Capital • N.V. NOM

COMPANY PROFILE

About Mucosis

Mucosis B.V. is a Dutch biotechnology company with a proprietary platform technology, Mimopath™, on which it develops mucosal vaccines with improved efficacy. Mucosis’s lead products are FluGEM™, a vaccine to prevent influenza; PneuGEM™, a vaccine to prevent diseases caused by pneumococcal bacteria; and SynGEM™, a vaccine to prevent RSV viral infections. Mimopath™-based vaccines can be administered needle-free in the nose and mouth, evoking a more natural immune response with a broader base of protection.

About Mimopath™ technology

The Mimopath™ technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed a robust technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigen-covered BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.

MANAGEMENT

Senior Management Govert Schouten, Chief Executive Officer Kees Leenhouts, CSOThomas Johnston, CBORoberto Grimaldi, CMOJolande Schoemaker, QA-officer & Qualified Person

Board of DirectorsJohn Lambert, ChairmanBarry BucklandAnnemieke WouterseWillem HazenbergOtto Postma

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Mymetics Corporation www.mymetics.com

CONTACTRonald Kempers CFO & COO

ADDRESSRoute de la Corniche 4 1066 Epalinges Switzerland

TELEPHONE+41 21 653 4535

FAX+41 21 653 2473


YEAR FOUNDED2001

FINANCIAL SUMMARY

Mymetics is a development stage company and has not generated significant revenues until now.

The company has been mainly financed though private HNWI through a mixture of equity and convertible debt.

More info see SEC filings

COMPANY PROFILE

Mymetics Corporation is a Swiss-based biotechnology company registered in the US (OTC BB: MYMX) developing next-generation preventative vaccines for infectious diseases. Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which for some pathogens may be essential for the development of an effective prophylactic vaccine. Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex Virus. The company’s HIV-1 vaccine has completed a Phase I clinical trial in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while RSV and HSV vaccine candidates are in the preclinical phase. The Influenza vaccine has been out-licensed to Solvay Pharmaceuticals (now Abbott) and has successfully completed a Phase I. For further information, please visit www.mymetics.com

MANAGEMENT

Jacques-François Martin, Chairman and CEODr Sylvain Fleury, CSO Ronald Kempers, CFO & COO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Neuronix Ltd www.neuronixmedical.com

CONTACTSEyal Baror CEO

Orly Bar VP Marketing

ADDRESSPOB 16 Yoqne’am Israel 20692

TELEPHONE+972-4-9038600

Eyal Baror 972-54-4932572

Orly Bar 972-54-3221018

FAX+972-4-9831938


YEAR FOUNDED2008

FINANCIAL SUMMARY

As of today, an amount of over US$ 5.5 M was invested in Neuronix. In addition, Company secured two grants from the Israeli Chief Science Office, amounting to 1.3MUSD.

Neuronix plans to raise an additional round during the 2012 first half, to enable completion of the US-FDA multi-center study, as well as marketing of its NeuroAD system in Europe.

COMPANY PROFILE

Founded in 2008, Neuronix’s mission is to provide long-term improvement in the quality of life for patients with Alzheimer’s Disease (AD), an incurable and terminal disease affecting 26 million people worldwide.

Neuronix Ltd. is the developer of the NeuroAD system for the treatment of mild to moderate Alzheimer’s disease. Based on the company’s core Non Invasive Cortical Enhancer (NICE™) technology (patent pending), the safe non-invasive system integrates Transcranial Magnetic Stimulation (TMS) and targeted Cognitive Training to induce Long Term Potentiation (LTP) in the specific regions of the brain affected by Alzheimer’s disease. In first round of clinical, NeuroAD has demonstrated the potential to slow down or stabilize disease progression, with results superior to those available with current medications. Further studies are currently underway in several medical centers around the globe (including Harvard University, USA). Offering a glimmer of hope and reprieve for sufferers and families, statistically significant results were achieved on both pilot as well as pivotal studies. The NICE™ technology has received CE approval for the indication of “treatment of mild-moderate Alzheimer Patients.

MANAGEMENT

Eyal Baror, CEO & Member of the BoardEyal brings over a decade of experience in R&D and in executive-level positions in several medical devices companies. A graduate of the prestigious Israel Defense Force’s Talpiot program, he holds a B.Sc. in Physics (cum-laude) from the Hebrew University of Jerusalem, and a M.Sc. in Physics (summa cum laude) from the Tel-Aviv University

Amir Katz, Vice President, R&DAmir brings extensive experience in the development of medical device systems to Neuronix. Prior to joining the company, he served as the R&D manager of a medical device company. Amir holds a B.Sc. in Mechanical Engineering, an MS in Biomedical Engineering and an MBA from the Technion–Israel Institute of Technology.

Dr. Ariela Alter, Vice President, Clinical and Regulatory AffairsIn her career spanning over a decade, Ariela has served in senior positions responsible for Clinical & Regulatory Affairs in several medical device companies, managing worldwide clinical trials and designing regulatory strategy. She has served as a Staff Associate in the New York-Presbyterian Pharmacology Department of the College of Physicians and Surgeons of Columbia University. Ariela holds a B.Sc. in Biology from the Technion-Israel Institute of Technology, an M.Sc. from Tel-Aviv University and a PhD from Bar-Ilan University.

Haim Solovatzik, CFOHaim has over 20 years of experience with global high-tech corporations in the fields of: Overall Financial Management, International Tax, international and local Mergers & Acquisitions, Information Systems, International Operations and Activity. Haim served as Finance and International Tax Director in Zoran Corporation, and previously Finance manager in i-Sight (a Clal

Electronics Industries subsidiary). Haim holds a BA in Economics and Accounting (CPA) from the Haifa University.

Ms. Orly Bar, VP MarketingIn the past 12 years, Ms. Bar has held several leading managerial and marketing positions both in healthcare organizations and HR companies. Orly holds a B.Ed. from the Oranim Institute, as well as completing her Mathematics Studies in Tehcnion-Israel Institute of Technology.

.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Neurotune AG www.neurotune.com

CONTACTSDr Bruno Oesch Executive Chairman / Head BD & L

Dr Armin Mäder CEO

ADDRESSWagistrasse 27a 8952 Schlieren Switzerland

TELEPHONE+41 44 200 21 95

FAX+41 44 200 21 80


YEAR FOUNDED2005

COMPANY PROFILE

Neurotune AG is a clinical stage, Swiss bio-pharmaceutical company founded in 2005 with currently 14 employees at its Zurich and Bioggio sites in Switzerland. The company is focusing on the discovery and development of drugs to treat disorders of the human peripheral and central nervous system with an emphasis on the modulation of synaptic transmission in the treatment of (1) chronic pain and (2) age-related muscle loss (sarcopenia). Both markets are commercially highly attractive.

Neurotune develops drugs up to phase II as well as diagnostics to market.

Neurotune’s unique approach on sarcopenia focuses on the neurotrypsin/agrin system which is key in the build-up and modulation of synapses, in particular at the neuromuscular junction (NMJ). The company has a very broad patent portfolio covering the neurotrypsin target, therapeutic biologics, neurotrypsin inhibitors, CAF based diagnostics, antibodies as well as animal models.

Beyond sarcopenia, the neurotrypsin/agrin system offers large development potential as it plays an important role in synaptic plasticity in the central and peripheral nervous system.

Neurotune’s lead compound for neuropathic pain (NT-11624) has successfully completed safety and tolerability endpoints (phase IIa) in HIV patients. Follow-on compounds are under development at preclinical stage. Neurotune’s small molecule based treatments for chronic pain are characterized by the absence of cognitive and sedative side effects, representing a major unmet medical need. Therefore, they are safe even for the elderly. Furthermore, their unique efficacy in disease animal models promises dramatic improvement in the treatment of neuropathic pain.

MANAGEMENT

Dr Armin W. Mäder, CEO/CFO14 years of experience in finance and life-science start-ups.

Dr Jan Willem Vrijbloed, CSO15 years of experience in preclinical and clinical development.

Prof Ruggero Fariello, MD, CMO Co-founder of Newron Pharmaceuticals, 30 years of clinical experience.

Dr Carlo Farina, Head of Chemistry Founder of Nikem, 30 years of senior pharma experience.

Board of DirectorsDr Bruno Oesch, Chairman, BD&L, founder of Prionics & Neurotune. 15 years experience in diagnostic development.

Gerhard Musshafen 30 years of experience in management and marketing in the pharmaceutical and diagnostics industry.

Dr Raimund Eckel 26 years of experience with strategic development in Boehringer Mannheim and Roche as well as executive management e.g. President of Boehringer Mannheim Japan.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Omnia Molecular, S.L. www.omniamol.com

CONTACTSRaphael Gernot Klingmann CEO

Dr Dariusch Mani, Board of Directors

ADDRESSBaldiri i Reixac, 15 Parc Científic de Barcelona 08028 Barcelona

TELEPHONE+34 934 020 158 (ES) +1 202 657 4327 (US)

Raphael Gernot Klingmann +34 664 654 674

Dr Dariusch Mani +41 774 394 290


YEAR FOUNDED2005 Incorporation2008 Begin of lab activity

FINANCIAL SUMMARY

Privately held (Venture Capital and Private Investors). $7 million USD invested to date, ca. $15 million USD required to reach positive cash flow, of which 50% is secured through existing investors and stakeholders.

A Round- Pre-clinical PoC (Animals): 1/10/2010 – $3 Million USD

Planned B Round- Lead Optimization: 1/1/2012 – $5 Million USD

Planned C Round- Clinical PoC: 1/1/2014 – $7 Million USD

• Currently seeking $2 million from new investors in B Round.

• Partnering for clinical co-development with pharma industry partner possible from lead optimization in 2012.

• Out-licensing/Exit possible from clinical proof-of-concept.

COMPANY PROFILE

– Omnia Molecular leverages its proprietary biotech platform to design and develop novel anti-infectives targeted at difficult-to-treat infections.

– Omnia’s business model is to partner with pharma industry from the proof of concept stage (efficacy in animal infection model) and out-license drug candidates at clinical proof of efficacy (phase IIa).

– Omnia has platform and new chemical entity assets. Our lead program targets MRSA, a multi-resistant bacteria which causes approximately 100,000 infections in hospitals per year, 20% of which are fatal.

– The Omnia platform is our patented, multi-parametric screening technology in which activity against the pathogen target is measured inside a human cell. Our platform thereby enables us to design and optimize new chemical entities against target.

– Omnia is led by professional management team with long-standing, international experience in the pharmaceutical industry and is advised by highly reputed members of its scientific board.

– Our molecular target is Aminoacyl-tRNA Synthetases (aaRS) aaRS Inhibition is a proven mode of action for anti-infectives and validated in the marketplace through the commercial success of Mupirocin (Bactroban®).

– Our competitive advantage is to shorten development time-lines and increase probabilities of success in the later stages of development. The net effect is to increase productivity and reduce risk and costs.

– Probabilities of success in clinic are increased through multi-parametric information on drug effect on human cells in the early stages of development.

– Our platform technology can be applied to a broad spectrum of pathogens including Pseudomonas, Klebsiella, Helicobacter, Actinobacter, Mycoplasma, Tuberculosis, Mycosis and Malaria.

MANAGEMENT

Raphael Gernot Klingmann, CEOBSci, MBA (IESE), 20 years international pharma leadership positions in USA, Germany and South Africa with Bayer, Solvay and Abbott, including 8 years global strategy/business development director, 5 years as CEO of South African subsidiary.

Dr Lluís Ribas de Pouplana, CSOFounder, ICREA Research Professor and PI at the Institute for Research in Biomedicine. Founder of Omnia Molecular, 18 years experience with Aminoacyl-tRNA synthetases. PhD Univ. of Edinburgh, Scientist M.I.T. (93-97), Assistant Professor The Scripps Research Institute (97-03).

Dr Oscar Rey PuiggròsMBA (ADE-Ramon Llull), 8 years experience in Drug Discovery Laboratorios SALVAT & Omnia Molecular, background in

Molecular Modeling, Theoretical Chemistry & Medicinal Chemistry.

Maurici Torra, CFOMBA (ESADE), 10 years experience on SMEs, includes 2 years on Venture Capital.

Dr. Dariusch Mani, BoDMBA (IESE), 20 years international experience pharmaceuticals & biotech, 12 years CEO, Schering AG, Madaus, LGP.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

ORCA Therapeutics BV www.orca-therapeutics.com

CONTACTJanneke Meulenberg, PhD CEO

ADDRESSDe Boelelaan 1118 1081 HZ Amsterdam The Netherlands

Postal address:PO Box 7057 1007 MB Amsterdam The Netherlands

TELEPHONE+31 204441826

FAX+31 204442126

EMAIL meulenberg @orca-therapeutics.com

YEAR FOUNDED2005

FINANCIAL SUMMARY

Current investor: Aglaia Oncology Seed Fund BV.

COMPANY PROFILE

ORCA Therapeutics B.V. (ORCA) is developing a pipeline of innovative anticancer therapies based on the highly promising approach of oncolytic viruses. ORCA’s value proposition is based on using its proprietary technologies in the field of Oncolytic Replication Competent Agents. ORCA’s lead product ORCA-010 is a new oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA-010 has up to ten thousand fold higher oncolytic potency as compared to current state of the art oncolytic adenoviruses in a variety of cancer cell lines and ORCA is currently developing ORCA-010 for its first study in man.

MANAGEMENT

Dr Janneke Meulenberg, PhD, CEODr Victor van Beusechem, PhD, CSO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Oxford BioMedica plc www.oxfordbiomedica.co.uk

CONTACTDr Alex Lewis Director Corporate Activities & Strategy

ADDRESSOxford BioMedica plc Medawar Centre Robert Robinson Avenue Oxford Science Park Oxford OX4 4GA United Kingdom

TELEPHONE+44 (0) 1865 783000

FAX+44 (0) 1865 783001


YEAR FOUNDED1995

FINANCIAL SUMMARY

The Company’s net cash balance at 31 December 2010 was £12.3 million. The placing and open offer which closed on 10 January 2011 raised £18.4 million net of expenses. At 31 March 2011 the Company had a net cash balance of £24.6 million (unaudited).

COMPANY PROFILE

Oxford BioMedica plc (LSE:OXB) is a biopharmaceutical company developing innovative treatments to improve the lives of patients with high unmet needs. Our mission is to build a top-tier profitable biopharmaceutical company founded on the successful development and commercialization of novel gene-based medicines.

Oxford BioMedica has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field.

Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax®, a therapeutic vaccine for multiple solid cancers, which is in Phase II development for the treatment of hormone refractory prostate cancer.

The Company has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson’s disease, in Phase I/II trial; RetinoStat®, a novel gene-based medicine for wet AMD, in Phase I/II and StarGen®, a novel gene-based medicine for the treatment of the inherited juvenile macular degeneration disease, Stargardt’s disease, Phase I/II.

Oxford BioMedica has collaborations with Sanofi, Wyeth, Sigma-Aldrich, MolMed and VirXsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.

MANAGEMENT

John Dawson, Chief Executive OfficerStuart Naylor, Chief Scientific OfficerAndrew Wood, Chief Financial OfficerPeter J. Nolan, Senior Vice PresidentAlex Lewis, Director

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Pantec Biosolutions AG www.pantec-biosolutions.com

CONTACTSDr Christof Böhler Chief Executive Officer

ADDRESSPantec Biosolutions AG Industriering 21 9491 Ruggell Liechtenstein

TELEPHONE+423 377 78 00

FAX+423 377 78 99

[email protected] Christof.boehler @pantec-biosolutions.com

YEAR FOUNDED2005

COMPANY PROFILE

Pantec Biosolutions specialises in microporation technology. The Company´s P.L.E.A.S.E.® (Precise Laser Epidermal System) platform features a safe (Class I), precise treatment profile, customizable settings and a compact design. P.L.E.A.S.E. offers new treatment options in aesthetic and traditional dermatology as well as combination treatments –i.e. microporation and transdermal delivery of biopharmaceuticals.

MANAGEMENT

Dr Christof Böhler, Chief Executive OfficerSven Rohmann MD, PhD, Chief Business OfficerThomas Bragagna, Chief Technology OfficerDr Norbert Clemens, Clinical Director, as permanent Consultant

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Pevion Biotech AG www.pevion.com

CONTACTEvert Kueppers Chief Executive Officer

ADDRESSWorblentalstrasse 32 CH – 3063 Ittigen/Bern Switzerland

TELEPHONE+41 31 550 4444

FAX+41 31 550 4445


YEAR FOUNDED2002

FINANCIAL SUMMARY

The two founders, Berna Biotech and Bachem, provided CHF 20 million as start-up capital. In August 2007, the Company closed a CHF 15 million series A financing round with new investors BZ Bank Aktiengesellschaft, BB Biotech Ventures and Core Capital Partners, as well as, the existing investor Bachem AG. After the acquisition of Berna Biotech by Crucell NV in 2006, Crucell’s participation was bought out in November 2007. In September 2010, Pevion secured additional CHF 10 million in financing from its current investors.

COMPANY PROFILE

Pevion Biotech AG is a fully independent Swiss vaccine company that develops innovative vaccines for unmet medical needs based on its clinically and commercially validated virosome technology. Its proprietary clinical pipeline includes a first-in-class candidiasis vaccine. A clinical stage malaria vaccine candidate has been successfully out-licensed, and the Company’s technology has been licensed for use as an HIV vaccine currently in human trials. Pevion has in-house development capability and expertise, including a state-of-the-art and industrially scalable GMP manufacturing process. Located near Bern, Pevion was established by its founding fathers, Bachem AG (SWX: BANB) and Berna Biotech (now Crucell, a Johnson & Johnson subsidiary). To date, Pevion has raised a total of CHF 45 million to date from its founders and investors, BZ Bank, CCP and BB Biotech Ventures.

MANAGEMENT

Evert Kueppers, Chief Executive OfficerUrs Berchtold, Head of Finance Christian Moser, DVM, PhD, Head of ResearchMario Amacker, PhD, Head of Process Development & ManufacturingChristian Spyr, PhD, Head of Project Management & Clinical Development

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Phylogica Ltd www.phylogica.com

CONTACTSDr Paul Watt Chief Executive Officer

Nick Woolf [SPEAKER] Chief Financial Officer & VP Corporate Development

ADDRESS100 Roberts Road Perth Western Australia 6008 Australia

TELEPHONE+61 8 9382 8888

FAX+61 8 9382 1766


YEAR FOUNDED2003

FINANCIAL SUMMARY

2005: IPO on ASX

Equity raised: A$25M

COMPANY PROFILE

Phylogica is a biotechnology company based in Perth, Australia and Oxford, UK, which provides peptide drug discovery services to the Pharmaceutical industry.

Phylogica has discovered and patented a unique proprietary class of targeted peptide therapeutics (Phylomer® peptides). These peptides exhibit competitive therapeutic, manufacturing, and commercial advantages over other more traditional targeted biologics such as proteins, monoclonal antibodies and most current therapeutic peptides.

Libraries of billions of Phylomers have been constructed, which constitute the most structurally diverse set of peptides available, resulting in a higher quality and quantity of hits. Current partners include Roche, Medimmune/AstraZeneca and Pfizer.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Phytopharm plc www.phytopharm.com

CONTACTSTim Sharpington CEO

Patrick Howson Head of Preclinical Research

ADDRESSPhytopharm plc Lakeview House 2 Lakeview Court Ermine Business Park Huntingdon PE29 6UA UK

TELEPHONE+44 1480 437697

FAX+44 1480 417090


YEAR FOUNDED1996

FINANCIAL SUMMARY

In line with our virtual operational structure, we continue to outsource the majority of our operations to specialist external organisations enabling us to operate with a low headcount and minimal infrastructure. This lean operational structure confers substantial cost and technical benefits as the nature and range of our activities change as our programmes progress through the various stages of development. Efficiency and cost control continue to be a key focus.

Phytopharm raised £24 million in December 2009 to provide the resources to progress the development of its pharmaceutical programmes. Cash at 31 March 2011 totalled £20 million.

COMPANY PROFILE

Phytopharm is a development stage biopharmaceutical company based in Huntingdon, UK and listed on the London Stock Exchange (LSE:PYM).

The company’s main focus is in neurodegenerative disease. Phytopharm’s lead products are first in class, small molecule neurotrophic factor inducers which have the potential to be important new treatments by protecting neuronal degeneration and providing true disease modifying characteristics.

With lead programmes in Parkinson’s disease, glaucoma and ALS Phytopharm is approaching important data milestones over the coming 2 years.

The company will seek licensing partners for its products when key development milestones are achieved, and also seeks to add its pipeline with via synergistic alliances.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

PIQUR Therapeutics AG www.piqur.com

CONTACTSVladimir Cmiljanovic, Ph.D.

Andreas.Emmenegger, EMBA

ADDRESSPIQUR Therapeutics AG Hohe Winde-Strasse 120 CH-4059 Basel Switzerland

TELEPHONE+41 61 695 3140

FAX+41 61 267 3566


YEAR FOUNDED2011

COMPANY PROFILE

Founded in 2011 as a spin-off company of University of Basel, PIQUR Therapeutics is an early stage venture biopharmaceutical company developing best-in-class, 3rd and 4th generation cancer therapeutics targeting the PI3K-Akt-mTOR pathway. With its 3rd and 4th generation agents, PIQUR is confident that it is the leader in the development of drugs tackling the PI3K cancer pathway.

The PI3K-Akt-mTOR cancer pathway is considered one of the three most important cancer pathways and is associated with many tumor types including pancreatic cancers, gliomas, thyroid, breast, non-small cell lung, gastric, gastro-intestinal stromal and bile duct cancers (Liu et al., 2009, Nature Reviews Drug Discovery).

Some 2nd generation agents have reached the clinic and have demonstrated that PI3K/mTOR inhibition is feasible – providing clinical proof of concept. However, these products have fallen short of efficacy and tolerance requirements and new generations of more effective and better tolerated agents are needed.

PIQUR’s knowhow and leadership position, backed by its global network of PI3K development specialists and its collaborators within the Oncology Unit of Basel University Hospital, have been responsible for the creation of PIQUR’s novel 3rd and 4th generation cancer-fighting agents which have overcome the complex dual PI3K-mTOR inhibition and physico-chemical problems faced by other companies, providing optimal therapies, tailored to the unique needs of each cancer.

MANAGEMENT

Dr Vladimir CmiljanovicProf Matthias WymannProf Bernd GieseAndreas EmmeneggerRalf Rosenow

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

ProFibrix BV www.profibrix.com

CONTACTSJan Öhrström CEO

Jaap Koopman CSO

ADDRESSZernikedreef 9 2333 CK, Leiden The Netherlands

TELEPHONE+31 888 669665

FAX+31 715 181340


YEAR FOUNDED2005

COMPANY PROFILE

ProFibrix leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the field of hemostasis. Fibrocaps™, the proposed name of the company’s lead biologic, is being studied to help stop bleeding during surgery and after trauma injury. A dry powder based on a mixture of fibrinogen and thrombin, Fibrocaps is a ready-to-use preparation designed to be stable at room temperature and applied in different formats, including sprays and bandages. Fibrocaps is currently wrapping up Phase 2 clinical studies and is scheduled to enter into a final pivotal Phase 3 study in 2012.

MANAGEMENT

Jan Öhrström, CEOJaap Koopman, CSOArnoud Dijkstra, CBOMartijn Meijer, VP FinanceEliane Schutte, CDOPaul Frohna, CMOLinda Zuckerman, VP Preclinical

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

PSites Pharma GmbH www.psites.de

CONTACTSDr Rolf Witte CEO

Dr Ricardo Biondi CSO

ADDRESSJugenheimer Str. 29 60528 Frankfurt Germany

TELEPHONE+49 211 851 11

FAX+49 211 617 851 51


YEAR FOUNDED2011

FINANCIAL SUMMARY

PSites has been awarded by a new € 2,9 M. GO-Bio grant and PSites Pharma GmbH is looking to get its current A round of € 7 M completed where € 1.5 M are still open.

COMPANY PROFILE

PSites Pharma GmbH is a spin-off from the University Frankfurt, developing the next generation of kinase inhibitors.

Based on the discovery of a non-ATP-competitive binding site for AGC- protein kinases in 2000, PSites has developed a complete platform of special screening systems, libraries and other tools for the development of very specific kinase inhibitors.

First lead structures for lung cancer and diabetes had shown very promising in vivo results.

PSites is looking for research collaborations to develop clinical candidates for selected, to be agreed kinase targets.

MANAGEMENT

Dr Rolf Witte, CEODr Ricardo Biondi, CSO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Riboxx GmbH www.riboxx.com

CONTACTDr J. Rohayem (CEO) Chief Executive Officer

ADDRESSRiboxx GmbH Pharmapark Radebeul, Meissner Str. 191, 01445 Radebeul Germany

TELEPHONE+49 351 833 6010

FAX+49 351 833 60139


YEAR FOUNDED2009

FINANCIAL SUMMARY

The company is VC funded and generates revenues through direct sales and distribution in Germany and Europe.

The company has successfully launched its products and services in 2010 generating stable income with more than 80 customers. The company rapidly increases its market share and is currently expanding its technology into therapeutic and diagnostic areas.

COMPANY PROFILE

Riboxx has developed a new technology to generate siRNA/miRNA candidates with strongly enhanced silencing activity and attractive in vivo behaviour to facilitate therapeutic and diagnostic applications.

Riboxx has developed its innovative tools for gene silencing in vivo and secured these with trademarks such as the IVORI® in vivo siRNA, the CONTRAmir® and CONmir® as well as an innovative synthesis process of RNA in large scale termed ENOVA®.

The IP portfolio of Riboxx relates mainly to three fields of inventions: A new class of IN VIVO siRNA, RNA/siRNA/miRNA synthesis and analytics, biocatalysis of chemically modified RNA/siRNA/miRNA.

The IP portfolio of Riboxx includes ten international patents families with a granted patent in EU, as well as many brands among them “Riboxx®”, “RNA interference in a box®”, “ENOVA®”, “CONTRAmir®” and “CONmir®”.

Riboxx is currently searching for partnerships to further develop the diagnostic and therapeutic potential.

MANAGEMENT

Dr Jacques Rohayem, MBA, MD/PhD, MSc, CEO and Founder

The company has so far 18 employees and four departments: Executive and Finance, Production and Quality Management, Research and Development, and Marketing and Sales.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

SANIFIT Laboratoris, S.L. www.sanifit.com

CONTACTSSwitzerlandDariusch Mani CEO

SpainJoan Perello CSO

ADDRESSSANIFIT Laboratoris Parc Bit, Building Disset 07121 Palma de Mallorca SPAIN

TELEPHONE+34 971 439 925

SwitzerlandDariusch Mani+41 77 4394 290

SpainJoan Perello +34 647 485 999

FAX+ 34 871 962 545


YEAR FOUNDED2007 (activities commenced)

FINANCIAL SUMMARY

Privately held by VC, founders and private investors. Total funding so far 6m€. Good access to public funds, strong track record meeting milestones. To conclude clinical trials (Phase I + II) and reach positive cash flow 20m€ required. Existing stakeholders provide up to 50%. Seeking commitment of 10-12m€ from new investors.

• B-Round 5m€ end of 2011

• C-Round 10m€ 2013.

Out-licensing of the dental products generates revenues from 2012. Positive overall cash flow from partnering is expected in 2015.

COMPANY PROFILE

Sanifit offers a new approach for calcification disorders, with a pipeline focused on prescription medicines (Rx) and selected OTC products. The international management team has proven track record and long industry experience.

The business model is to develop the products up to clinical prove of concept and out-license/partner for final development and commercialization.

The lead Rx product (SNF472) is entering Phase I clinical trials. It targets renal dialysis patients reducing cardiovascular calcification, related to high morbidity and mortality. The pre-clinical pipeline includes drugs for severe chronic diseases in the cardiovascular and renal areas.

The IP protected technology covers also the use in medical nutrition and medical devices, where Sanifit explores applications jointly with partners.

OTC dental care products with outstanding clinical efficacy were successfully developed and are in the commercial partnering/launch phase.

Value realization through spin-offs of OTC and major licensing deals for Rx with attractive exit potential in 2014/15.

MANAGEMENT

Dariusch Mani, Ph.D., MBA, CEO25 years international experience, CEO at large multinational and start-up pharma companies, founder, PE fund investor

Pieter Joubert, M.D., CMO30 years industry experience, former Global Head Clinical Pharmacology, Roche, Switzerland, pharma industry advisor,

Professor Pharmacology in SA and UK

Joan Perelló, Ph.D., CSO Founder of Sanifit and co-inventor in key IP. 10 years R&D experience, founder/president Biotech cluster

Bernat Isern, Ph.D., COO Founder of Sanifit and co-inventor of key IP. 10 years R&D management

Rubén Henríquez, Ph.D., MBA, CBO15 years industry experience in R&D, IP, licensing and VC deals at Novartis (Switzerland) and Zeltia Group (Spain)

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Santhera Pharmaceuticals www.santhera.com

CONTACTThomas Staffelbach VP Head Public & Investor Relations

ADDRESSHammerstrasse 49 4410 Liestal Switzerland

TELEPHONE+41 61 906 89 50

Thomas Staffelbach +41 906 89 47

FAX+41 61 906 89 51


YEAR FOUNDED2004

FINANCIAL SUMMARY

Fiscal year 2010 (ended December 31, 2010, CHF thousands)Cash reserves: 43,682Cash burn: - 9,638Total revenue: 20,609Net sales: 3,469Operating expenses: - 29,694Operating result: - 8,711Net loss: - 11,256

COMPANY PROFILE

Santhera is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative therapies for severe orphan and niche indications with a focus on neuromuscular and neurodegenerative diseases, areas of high unmet medical need which includes many orphan indications with no current therapy.

Santhera’s pipeline consists of three compounds in seven indications. The first product, Catena®, to treat Friedreich’s Ataxia is marketed in Canada. In Europe, the EMA is currently reviewing the Company’s MAA in Leber’s Hereditary Optic Neuropathy. The drug is also being investigated in a Phase III study in Duchenne Muscular Dystrophy; in a Phase II study in MELAS syndrome (in collaboration with Columbia University of New York City); and in Phase I/II in Primary Progressive Multiple Sclerosis (in collaboration with the US National Institute of Neurological Disorders and Stroke). Commercial rights in Europe for Duchenne Muscular Dystrophy are licensed to Takeda Pharmaceutical.

Santhera’s second compound fipamezole is currently prepared for Phase III development as potentially first treatment of levodopa-induced Dyskinesia in Parkinson’s Disease. Development and commercialization rights outside North America and Japan are partnered with Ipsen.

Santhera’s third compound omigapil was in-licensed from Novartis for development in Congenital Muscular Dystrophy. Preparation for Phase II/III development is ongoing.

For further information, please visit the Company’s www.santhera.com.

MANAGEMENT

Klaus Schollmeier, Chief Executive [email protected] Phone +41 906 89 62

Barbara Heller, Chief Financial [email protected] Phone +41 906 89 54

Thomas Meier, Chief Scientific [email protected] Phone +41 906 89 64

Helmut Kessmann, Chief Business [email protected] Phone +41 906 89 56

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Scil Proteins GmbH www.scilproteins.com

CONTACTFrank Ubags Chief Financal Officer

ADDRESSScil Proteins GmbH Heinrich-Damerow-Strasse 1 06120 Halle (Saale)Germany

TELEPHONE+49 345 27996 330

FAX+49 345 27996 332


YEAR FOUNDED2000

FINANCIAL SUMMARY

Financing Round 2011: €24 mm

COMPANY PROFILE

Scil Proteins is a biopharmaceutical company discovering and developing Affilin® molecules and working with industry partners in the development and manufacture of protein therapeutics and diagnostics. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins’ discovery platform is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems. Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer and other therapeutic areas. It also offers the technology to the industry for collaborative discovery and development partnerships. With a longstanding expertise in protein production and development, Scil Proteins also offers GMP contract bio manufacturing and process development to biotech and pharma companies. Scil Proteins is a well-established private company located in Halle, Germany.

To learn more about Scil Proteins please visit www.scilproteins.com

MANAGEMENT

Dr Ulrike Fiedler, CEODr Ulrich Haupts, CBO Dr Henning Afflerbach, CBO Frank Ubags, CFO

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Siena Biotech S.p.A www.sienabiotech.com

CONTACTSDr Russell Thomas Director of Project Operations and Alliances

Dr Giovanni Gaviraghi CEO

ADDRESSSiena Biotech S.p.A. Strada del Petriccio e Belriguardo, 35 53100 Siena ITALY

TELEPHONE+39 0577 381 409

FAX+39 0577 381 323


YEAR FOUNDED2000

FINANCIAL SUMMARY

Siena Biotech is a privately held company founded by its major shareholder, the Monte dei Paschi di Siena Foundation.

The Monte dei Paschi di Siena Foundation is a non-profit organization operating totally within the sphere of private law which pursues aims of social utility through the management of its assets, derived primarily from its major stake in Monte dei Paschi di Siena Bank.

Siena Biotech is an operational arm of Monte dei Paschi di Siena Foundation to achieve its objectives.

COMPANY PROFILE

Siena Biotech is a drug discovery and development company with a consolidated portfolio of disease modifying small molecule therapeutics for oncology and neurodegenerative diseases aiming to prolong and improve the quality of patients’ lives

Siena Biotech has secured top level management executives leading an established team of talented international scientists. Combining our drug discovery and development expertise with an integrated platform of cutting edge technologies housed in a purpose-built research centre, we have developed a diversified pipeline of partnered, in-licensed and proprietary products for oncology and neurodegenerative indications, including rare diseases.

Siena Biotech has delivered candidates for Alzheimer Disease in partnership with leading pharmaceutical companies. In July 2011 Siena Biotech received a further undisclosed payment from Roche based on the achievement of a key milestone in a project aimed at developing disease-modifying therapies for Alzheimer’s disease.

Our fight to develop a disease modifying therapy against Huntington’s Disease, a devastating hereditary neurodegenerative disease with no cure, has lead us to clinical development of SEN196, a Sirtuin 1 inhibitor in licensed from Elixir Pharmaceuticals. The product is currently in Phase II trials in patients with HD and has achieved Orphan Drug status for HD from the FDA, the EMEA and the Department of Health and Ageing in Australia. In 2011 Siena Biotech signed an alliance with CHDI aimed at the validation of novel therapeutic targets for HD.

In the field of oncology, Siena Biotech has developed significant experience in both the Hedgehog and Wnt signalling pathways. Siena Biotech has signed a collaboration agreement with the Experimental Therapeutics Centre (ETC) and Singapore Immunology Network (SIgN), two research units under Singapore’s Agency for Science, Technology and Research (A*STAR). The collaboration leverages Siena Biotech’s expertise and equity of Wnt pathway modulators with ETC and SigN capacity to develop new drugs and targeted antibodies respectively, aiming to help millions of cancer and bone loss patients across the world.

MANAGEMENT

Giovanni Gaviraghi, CEO and General ManagerAlberto Faleri, Deputy DirectorRussell Thomas, Director of Portfolio Operations and Alliances

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

sigma-tau research Switzerland SA www.sigmatau.com

CONTACTSAlessandro Noseda CEO & GM

Francesca Mancuso Administrative Assistant

ADDRESSPO BOX 1823 Mendrisio Stazione-Via Motta 2a 6850 Mendrisio (CH)

TELEPHONE+41 91 640 4051

FAX+41 91 640 4059

EMAIL alessandro.noseda @st-research.ch francesca.mancuso @st-research.ch

YEAR FOUNDED2004

COMPANY PROFILE

sigma-tau Research Switzerland S.A. is an R&D Company of the sigma-tau Group specialized in the development of novel and innovative drugs.

sigma-tau Research Switzerland is mainly focused on highly specialized therapeutic areas as oncology, where STRCH is developing new anticancer agents acting on innovative targets, either as small molecules (e.g. hearanase inhibitors) or monoclonal antibodies (e.g. anti-Met).

It also provides technical R&D (chemical and analytical development) and clinical development competences and services.

MANAGEMENT

Marco Brughera, PresidentAlessandro Noseda, CEO & GM

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Silence Therapeutics plc www.silence-therapeutics.com

CONTACTSMr Thomas Christély Chief Operating Officer, Silence Therapeutics plc and Chief Executive Officer, Silence Therapeutics AG

Mr Max Herrmann Finance Director & Company Secretary

Dr Klaus Giese Chief Scientific Officer

ADDRESSSilence Therapeutics plcThe Royal Institution of Great Britain 21 Albemarle Street London W1S 4BS Great Britain

Silence Therapeutics AGRobert – Roessle – Strasse 10 13125 Berlin Germany

TELEPHONE+44 20 7491 6520 (London) +49 30 9489 2800 (Berlin)

FAX+44 20 7491 6521 (London) +49 30 9489 2801 (Berlin)

EMAIL t.christely @silence-therapeutics.comm.herrmann @silence-therapeutics.comk.giese @silence-therapeutics.com

YEAR FOUNDEDOctober 1994

COMPANY PROFILE

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.

SILENCE offers one of the most comprehensive RNAi therapeutic platform available today, comprised of proprietary delivery technologies, potent short interfering RNA (siRNA) sequences and innovative siRNA structural features. The Company has developed a novel, proprietary siRNA technology (AtuRNAi) and proprietary systemic delivery systems for siRNA (AtuPLEX, DACC and DBTC).

SILENCE pipeline, which includes five product candidates in clinical development, consists of both partnered and internal programs. Silence’s lead compound Atu027 is currently in a Phase I clinical study for the treatment of solid tumours. 24 patients had been treated with Atu027, and to date, the compound has been shown to be safe and well tolerated. Interim data have been presented at the American Society of Clinical Oncology Annual Meeting in June 2011.

In addition to Silence’s partnerships with Quark/Pfizer ($95m milestone payments) and Quark/Novartis ($80m milestone payments), Silence has active collaborations with AstraZeneca ($15m upfront/$400m milestone payments) and Dainippon Sumitomo ($2m upfront).

TECHNOLOGY

SILENCE believes that this broad and proprietary RNAi therapeutics and delivery technologies base can support and advance multiple partnerships with the pharmaceutical industry across a diverse range of therapeutic opportunities.

The Company has developed a novel, proprietary siRNA technology (AtuRNAi) and proprietary systemic delivery systems for siRNA (AtuPLEX, DACC and DBTC). These sophisticated and flexible delivery options allow Silence to offer potential partners a choice of technologies to deliver RNAi molecules to a broad range of targeted diseased tissues.

SILENCE has a strong IP portfolio providing proprietary position and freedom to operate. The Company has performed more than 100 pre-clinical studies in different animal models (mouse/rat/non-human primate).

Out of 13 clinical siRNA programs worldwide as of April 2011 there are 5 clinical programs (four in phase II and one in Phase I) with SILENCE’s AtuRNAi molecules of which four are developed by SILENCE’s partners Pfizer/Quark and Quark / Novartis which confirms SILENCE’s leadership in the field of siRNA therapeutics.

Summary Products:- PF-4523655(AtuRNAi), (DME, AMD)

partner: Pfizer/Quark Pharma (Phase II);- QPI-1002 (AtuRNAi), (Prevention of Delayed Graft Function, Acute Kidney Injury) partner: Quark/Novartis

(Phase II );- Atu027 (AtuRNAi) (GI, Lung & Other Cancers, Phase I)- Atu111 (AtuRNAi) (Acute Lung Injury); Internal (Preclinical)- Atu134 (AtuRNAi) (Solid Tumors); Internal (Preclinical)- Atu195 (AtuRNAi) (Solid Tumors) Internal (Preclinical)

MANAGEMENT

Senior Management Thomas Christély, COO of Silence Therapeutics plc and Chief Executive Officer of Silence Therapeutics AG Max Herrmann, Finance Director & Company SecretaryDr Klaus Giese, CSO Dr Jörg Kaufmann, Vice President Research

Board of Directors Jerry Randall, ChairmanMax Herrmann Dr David Mack Dr David U’Prichard Annette Clancy

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Soluprin Pharmaceuticals, Inc.

CONTACTSStan Yakatan +786 229 9795

Dr Phil Felice +631 379 4262

ADDRESS245 33rd Street Hermosa Beach, Califiornia 90254 USA

YEAR FOUNDED2005

FINANCIAL SUMMARY

Capital invested: Private investment by founders 3 mm+.

COMPANY PROFILE

For years the pain market has been trying to identify a form of aspirin that is non addicting, has minimal side effects, and can be delivered both in an injectable and IV form to patients..After 5 years of research such a product has been developed, patented and manufactured in small quantities. A powder form is being developed for the OTC market and a sublingual, liquid form an IV drip are being developed for the ethical market.

Soluprine is ready to be introduced to the investment market as it is ready to enter clinical trials for at least 9 indications. The company is seeking 3-5 million dollars for the complete clinical trial program, which is being managed by Covance.

Please contact StanYakatan for additional information..

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Stabilitech www.stabilitech.com

CONTACTSDr Barbara Domayne-Hayman CEO

ADDRESSStabilitech Ltd London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH UK

TELEPHONE+44 20 7691 3567 +44 7771 635450


YEAR FOUNDED2004

FINANCIAL SUMMARY

Stabilitech is funded by business angels and non-dilutive funding. The company has raised a total of £7.5 million so far, in three funding rounds (including seed). Stabilitech has won a contract with DTRA, part of the US Department of Defense, with a value of up to $4 million over 3 years.

COMPANY PROFILE

Stabilitech has developed a novel proprietary technology which stabilizes vaccines, biopharmaceuticals and other biological products. The inspiration for the technology came from nature. It will enable the long term stable storage of vaccines and other biological products over a range of temperatures, and has been applied to a variety of vaccine and biopharmaceutical classes. Stabilitech’s approach involves the addition of selected excipients at optimised concentrations and ratios, followed by freeze drying. The excipients have all been previously used in clinical settings, and are inexpensive and readily available.

Stabilitech’s business model is to license the technology to pharma, biotech and animal health companies.

Stabilitech is a private company based in London, in the London Bioscience Innovation Centre.

MANAGEMENT

Dr Barbara Domayne-Hayman, Chief Executive OfficerDr Jeff Drew, Chief Scientific OfficerDr Stephen Ward, Development DirectorMs Donna Hackett, Commercial Director

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Syndax Pharmaceuticals Inc. www.syndax.com

CONTACTSDr Joanna Horobin Chief Executive Officer

Dr Bob Goodenow Chief Business Officer

Mr John Pallies Director, Finance

ADDRESSSyndax Pharmaceuticals, Inc. 460 Totten Pond Road, Suite 650 Waltham MA 02451 USA

TELEPHONE+1 781 419 1400

FAX+1 781 419 1420


YEAR FOUNDED2005

FINANCIAL SUMMARY

Series A:$49M

Investors: • Domain Associates • MPM Capital • Pappas Ventures • Avalon Ventures • Forward Ventures • MLC

Seeking Series B 2011.

COMPANY PROFILE

Syndax is a late-stage epigenetics oncology company focused on mechanisms of drug resistance in solid tumors with worldwide rights to entinostat. We recently completed a randomized, placebo controlled Phase 2 trial evaluating entinostat with Aromasin® in patients with advanced/metastatic breast cancer and are moving this program into phase 3 testing. Also, results from a placebo controlled, randomized phase 2 study showed a four-month survival advantage when entinostat was added to erlotinib in patients with lung cancers expressing high levels of E-cadherin. In collaboration with investigators at Johns Hopkins University and the NCI, Phase 2 ‘double’ epigenetic clinical studies are being conducted with entinostat and the DNA methyltransferase inhibitor, Vidaza® in solid tumors, based on the objective clinical responses previously reported in a lung cancer trial.

Syndax was founded in 2005 by Eckard Weber, M.D., Domain Associates, and Ron Evans, Ph.D., Salk Institute. For more information, please visit www.syndax.com

MANAGEMENT

Senior ManagementJoanna Horobin, MD, Chief Executive OfficerBob Goodenow, Ph.D., Chief Business OfficerMiranda Rees, VP Product DevelopmentWilliam McCulloch, MB, ChB, FRCP, FFPM, Chief Medical OfficerCaryn Peterson, VP, Regulatory Affairs

Board of Directors/AffiliationDennis Podlesak, Chairman, Domain AssociatesKim Kamdar, Ph.D., Domain AssociatesSteven St. Peter, MD, MPM CapitalRosina Maar Pavia, MD, Pappas Ventures

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

Syntaxin Ltd www.syntaxin.com

CONTACTSDr Melanie Lee Chief Executive Officer

Dr Nigel Clark Chief Business Officer

Dr Phil Boyd Chief Finance Officer

ADDRESSSyntaxin Ltd Units 4-10 The Quadrant, Barton Lane Abingdon, Oxon, OX14 3YS UK

TELEPHONE+44 (0) 1235 552100

FAX+44 (0) 1235 552200


YEAR FOUNDED2005

FINANCIAL SUMMARY

The Company completed a £6m Series A financing with Abingworth in November 2005, and a £16m Series B financing led by SR One and Life Science Partners in October 2007, with Abingworth, Johnson & Johnson Development Corporation and Quest for Growth co-investing. In October 2010, a Series C round raised £18m and included participation from existing investors Abingworth, SR One, LSP, Johnson & Johnson Development Corporation, Quest for Growth, and new investors Ipsen, Lundbeckfond Ventures and Seventure. The funds will enable Syntaxin to maximise the potential of its innovative Targeted Secretion Inhibitor (TSI) technology platform, as well as take its lead internal Acromegaly programme into Proof of Concept studies.

COMPANY PROFILE

Syntaxin was founded in late 2005 through spin-out of intellectual property and scientists from the UK Health Protection Agency, Porton Down, and benefits from 15 years of research in the field of bacterial toxin engineering. The company holds dominant patents and know how in the design, manufacture and use of novel cell Targeted Secretion Inhibitors (TSI) based on engineered botulinum toxins. These drugs inhibit secretion from a specific target cell for a prolonged period after a single dose, so are convenient for treatment of chronic disease.

Cell secretion plays an important role in the development of numerous diseases including endocrine, metabolic disorders, certain cancers, as well as chronic pain. Syntaxin’s proprietory technology enables the generation of novel therapeutic proteins with broad applicability across these major disease areas.

MANAGEMENT

Dr Melanie Lee, Chief Executive OfficerDr Nigel Clark, Chief Business OfficerDr Phil Boyd, Chief Financial OfficerDr Jon Court, Chief Development Officer & Research DirectorDr Richard Jones, Chief Medical OfficerDr Keith Foster, Founder & Chief Technology Officer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

TD Vaccines A/S www.tdvaccines.com

CONTACTIngelise Saunders CEO

ADDRESSAspvej 12, Rauf DK-9520 Skørping Denmark

TELEPHONE+45 20203687


YEAR FOUNDED2009

PIPELINE

ACE527: ETEC Vaccine – ph II ACE920: ETEC/Campylobacter Vaccine – pre-clinical ACE393: Campylobacter Poultry Vaccine – pre-clinical

COMPANY PROFILE

TD Vaccines A/S is a Danish biotechnology company established in November 2009. The company is focused on the development of vaccines to protect against travellers’ diarrhoea (TD). Every year, millions of tourist and business travellers visit destinations in Asia, Africa and Latin America, and around half of these succumb to TD.

TD Vaccines’ lead programme is ACE527, an oral ETEC vaccine to protect against ETEC (Enterotoxigenic E Coli). ACE527 has completed Phase I trials in the US and have completed the Proof of Concept Phase II challenge trial in early 2011 with very encouraging results. There currently is no vaccine to prevent TD in the market.

Earlier in development, at a preclinical stage, is an oral combination vaccine, ACE920, designed to protect against ETEC and Campylobacter infections.

TD Vaccines is backed by the Danish venture capital investors Sunstone Capital, Vækstfonden and Dansk Erhvervsinvestering.

COLLABORATION

PATH, an international nonprofit global health organization, has been supporting the development of ACE527, specifically for use with children in resource-poor populations, and collaborated with TD Vaccines on the earlier trials.

MANAGEMENT

Ingelise Saunders, CEOPreviously CEO at Celltech Pharmaceuticals Ltd, ACE Biosciences A/S and Action Pharma A/S, and has held executive management positions at Novo Nordisk A/S.

Mike Darsley, CDONIH Fogarty fellow. Previously at IGEN Inc. VP research at Acambis where ACE527 program started, has led development throughout programme.

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

TiGenix NVwww.tigenix.com

CONTACTSEduardo Bravo Chief Executive Officer

Claudia D’Augusta, Chief Finance Officer

Mr Gil Beyen Chief Business Officer

ADDRESSTiGenix nv Romeinse straat 12/2 B-3001 Leuven Belgium

TELEPHONE+32 16 39 6060

FAX+32 16 39 6050


YEAR FOUNDED2000

FINANCIAL SUMMARY

Cash on 30/6/2011: EUR 25 mio.

COMPANY PROFILE

TiGenix NV (NYSE Euronext Brussels: TIG) is a public biomedical company that focuses on ‘Living Medicines’. The company is exploiting the power of cell therapy and regenerative medicine to develop durable treatments for damaged and diseased tissues. The company is the leader in cell therapy in Europe with facilities in Leuven (Belgium), Madrid (Spain), Cambridge (the United Kingdom) and Sittard-Geleen (the Netherlands).

TiGenix now has two products approved for marketing and sales in Europe:

ChondroCelect®, the company’s lead product for cartilage regeneration in the knee, is the first cell-based product that successfully completed the entire development track from research, over clinical development to central European registration as a medicinal product. ChondroCelect consists of characterized cultured chondrocytes derived from the patient’s own cartilage and is used for autologous chondrocyte implantation (ACI), a surgical procedure to treat cartilage defects. ChondroCelect received European Marketing Authorization as the first Advanced Therapy Medicinal Product and is reimbursed in Belgium.

ChondroMimetic™ is an off-the-shelf, collagen based implant for the treatment of small osteochondral (cartilage and underlying bone) defects. ChondroMimetic received CE-mark approval for the treatment of small chondral and subchondral lesions. It will be marketed as a procedure pack with the collagen implant preloaded in an accurate, easy to use delivery device.

TiGenix exploits its proprietary adult stem cell platform to develop a new generation of off-the-shelf cell-based products for the treatment of autoimmune and inflammatory diseases which to date represent an area of high medical unmet need.

TiGenix’ stem cell platform is based on an extensive preclinical and regulatory package that has been fully validated according to EMA requirements. The current pipeline includes Cx601 (orphan drug,) which received positive Phase IIa data for the treatment of complex perianal fistula in Crohn’s disease patients in 2010, Cx611, which entered Phase I/II development in rheumatoid arthritis and several other programs in earlier development.

MANAGEMENT

Eduardo Bravo, Chief Executive Officer Claudia D’Augusta, Chief Finance Officer Gil Beyen, Chief Business OfficerWilfried Daelemans, Chief Operating Officer

t back :: next u




VC PARTNERW

ELCOME

SPONSORS

WntResearchwww.wntresearch.com

CONTACTSBert Junno Member of the Board and CEO

Madeleine Nydahl

ADDRESSSödra Promenaden 69 211 38 Malmö

TELEPHONE+46 70 7772209

EMAIL Bert.junno @wntresearch.com Madeleine.nydahl @wntreseach.com

YEAR FOUNDED

2008

COMPANY PROFILE

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2008.

The focus and aim of WntResearch is to develop novel anti-metastatic therapies for the treatment of cancer patients meets a large unmet medical need.

The company has two projects Foxy-5 and Box-5. The lead project is Foxy-5 which is currently being tested in vivo models and is planned to enter and finalize phase 1 clinical trials in metastatic cancer in 2012.

MANAGEMENT

Tommy Andersson, Member of the Board and Chief Scientific Officer Appointed Professor in Experimental Pathology at the Medical Faculty, Lund University.

Peter Buhl, Chairman of the Board of WntResearch and clinical scientific advisor Co- Founder and CEO until 2010 of Topo Targets A/S, Denmark. Professor of Clinical Oncology University of Copenhagen, MD, DMSc.

Bert Junno, Member of the Board and CEO for WntResearch. Bert Junno has a M.Sc. in Physics from Lund University and a Ph.D. in Semiconductor Physics from the same university. Bert Junno is currently serving on the boards of Cardiovax llc., Taurus Energy AB, WntResearch AB, Galecto Biotech AB and on the advisory board of the Swedish Patent Office.




VC PARTNERW

ELCOME

SPONSORSt

back :: next u

Xention Limited www.xention.com

CONTACTDr Tim Brears Chief Executive Officer

ADDRESSXention Limited Iconix Park London Road Pampisford, Cambridge CB22 3EG United Kingdom

TELEPHONE+44 (0)1223 493900

FAX+44 (0)1223 493901


YEAR FOUNDED2002

FINANCIAL SUMMARY

Xention has so far raised £35 million over four rounds of venture capital financing. The company’s investors include Seroba Kernel Life Sciences, Forbion Capital Partners, MVM Life Science Partners, Crédit Agricole Private Equity, Spark Ventures, BTG International, Albany Ventures, Isis Equity Partners and Foresight Group.

COMPANY PROFILE

Xention specialises in the discovery and development of ion channel-modulating drugs. The Company is developing potential breakthrough drugs for atrial fibrillation (AF), an area of substantial unmet medical need in which Xention has developed considerable expertise.

AF is the most common cardiac arrhythmia facing physicians and the prevalence of AF is predicted to increase two- to three-fold in the next 50 years. It is estimated that between 15 and 25% of strokes are caused by AF.

Xention’s programmes are focused on the exciting new AF targets Kv1.5 and IKACh both of which are expressed only in the atria. We are thus developing atrial-specific therapeutics that maintain normal sinus rhythm to prevent the recurrence of AF.

Xention’s lead compound, XEN-D0103, is a highly potent and selective modulator of the voltage-gated potassium channel Kv1.5 and show excellent efficacy in pre-clinical in vivo models. This programme is currently in Phase 1 clinical development.

Xention has also developed highly potent and selective modulators of the potassium channel IKACh which are about to enter development.

In addition to its work on AF, Xention is undertaking early-stage ion channel discovery research in other therapeutic fields with third-party collaborators including Ono Pharmaceutical Co Ltd. and Grünenthal GmbH.

In late 2010, Xention demerged its overactive bladder interests into Provesica Ltd, a newly established company that will progress the TRPV1 antagonist XEN-D0501 through Phase 2 clinical development.

MANAGEMENT

Executive ManagementTim Brears Ph.D., Chief ExecutivePatrick M Round MB BS, FRCA, FFPM, Chief Medical OfficerJohn W Ford Ph.D., VP programme managementDavid J Madge PhD, VP, ResearchRebecca T Hemsley, Director of FinanceKeith McCullagh, Chairman

Partnering Organisations




VC PARTNERW

ELCOME

SPONSORSt

back :: next u

www.citigatedr.co.uk

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia.

Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors.

The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia.

Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).

Citigate Dewe Rogerson3 London Wall BuildingsLondon WallLondon EC2M 5SY

Tel: +44 (0)-207-638-9571

Citigate Dewe Rogerson

t back :: next u





VC PARTNERW

ELCOME

SPONSORS

www.collegehill.com/lifesciences

College Hill Life Sciences provides a full service communications consultancy focused on science-based sectors. Within the life science field we have established a leadership position by working in partnership with our clients to deliver high quality communications that build corporate value and promote leading edge products, technologies and services).

London Sue CharlesThe Registry, Royal Mint Court, London EC3N 4QN, UKT: +44 (0)20 7457 2020 F: +44 (0)20 7866 7900Email: [email protected]

Manchester Dr Eileen Paul / Chris Fisher Meadowside, Mountbatten Way, Congleton, CW12 1DN, UKTel: +44 (0)1260 296500 Fax: +44 (0)1260 296501Email: [email protected]

MunichDr Douglas PretsellAugustenstraße 79, 80333 Munich, GermanyTel: +49 (0)89 57 00 18 06 Fax: +49 (0)89 52 38 80 06Email: [email protected]

San Francisco Erik Clausen201 Spear Street, Suite 1100, San Francisco CA 94105, USATel: +1 (415) 230 5385Email: [email protected]

College HillLife Sciences





VC PARTNERW

ELCOME

SPONSORSt

back :: next u

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc.35 W. 35th Street, 5th Floor, New York, NY 10001-2205

Tel: 212.827.0020 Fax: 212.827.0028 Fax

Tiberend Strategic Advisors, Inc.

Regional Partners




VC PARTNERW

ELCOME

SPONSORS

www.biotop.de

BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region.

It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster.

The services provided by BioTOP include:

• Technology transfer science - industry

• Initiation and support of networks

• Support for technology-oriented start-ups

• Funding support for innovative projects

• Providing information on biotechnology

• Building and coordination of scientific and interdisciplinary networks

• Establishing contacts between experts from all disciplines

• Design and organization of events

• Public relations work for the biotech region Berlin-Brandenburg

For more information, including a database with comprehensive profiles of all companies and scientific work groups, please visit our website at www.biotop.de.

Dr. Kai Bindseil BioTOP Berlin-Brandenburg Fasanenstr. 85 10623 Berlin - Germany

Tel: +49 30 318 622 11Fax + 49 30 318 622 22

BioTOP Berlin-Brandenburg

t back :: next u

Regional Partners




VC PARTNERW

ELCOME

SPONSORSt

back :: next u

www.lifescienceaustria.at

Life Science Austria - LISA - is a program acting as a hub for people from all over the world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria.

Working with all existing life science clusters in the Austrian regions – ecoplus, human.technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy commercial development.

Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).

Austria Wirtschaftsservice Gesellschaft mbHUngargasse 371030 WienAustria

tel.: +43 (1) 501 75 - 0fax: +43 (1) 501 75 - 900email: [email protected]

Life Science Austria - LISA

Regional Partners




VC PARTNERW

ELCOME

SPONSORSt

back

www.swissbiotech.org

One Nation – One Biotech Cluster

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.

Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Further inquiries:SwissBiotechExecutive Office Tel. +41 (0)44 455 56 78

SwissBiotech

Organisers




VC PARTNERW

ELCOME

SPONSORS

www.sachsforum.com

Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefi ts accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia ExposureSachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies,including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long establishedrelationships with other financial press organisations globally, which allow further effective distribution onbehalf of its clients.

Eminent SpeakersSachs Associates is committed to ensuring that its events continue to provide forums with the participation ofthe most eminent speakers from the public and private sectors. Through its reputation and its long-establishedlocal relationships, the Company has attracted the very senior political and economic personalities as speakersat its events.

Sponsorship and Marketing Opportunities for forthcoming eventsSachs Associates has developed an extensive knowledge of the key individuals operating within the Europeanand global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at theforefront of the industry and provides a powerful tool by which to increase the position of your company in thismarket.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients.All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most outof attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:• Conference Sponsor – including workshops and social events• Exhibition stands• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please callZoe Harris on +44 203 463 4890.

Sachs Associates




VC PARTNERW

ELCOME

SPONSORS

www.sachsforum.comBI

OT

EC

H

IN

E

UR

OP

E

IN

VE

ST

OR

F

OR

UM

1st Floor Holborn Gate330 High Holborn

LondonWC1V 7QT

Tel: +44 203 463 4890Fax: +44 (0)20 7405 4411

We look forward to seeing you at:

5th Annual EUROPEAN LIFE SCIENCE CEO FORUM

PARTNERING & INVESTING inBiotech & Pharma Industry

28 – 29 February 2012 • Zurich

welcome sponsors vc partner 11th annual ......nyse euronext (nyx) is a leading global operator of...

Documents